: The AMEDEO Literature Guide

Home The Word Brain

My Amedeo

FAQ

Privacy

About

2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.

Tuberculosis

Free Subscription

Articles published in Int J Tuberc Lung Dis
Retrieve available abstracts of 464 articles:
HTML format

Single Articles

April 2024

PARREIRA PL, Fonseca AU, Soares F, Conte MB, et al
Chest X-ray evaluation using machine learning to support the early diagnosis of pulmonary TB.
Int J Tuberc Lung Dis. 2024;28:171-175.
PubMed Abstract available

DOGO FM, Ate S, Agossou K, Menon S, et al
Decentralising DOT for drug-susceptible TB from the health facilities to the community level in Togo.
Int J Tuberc Lung Dis. 2024;28:195-201.
PubMed Abstract available

ILAIWY G, Heysell SK, Lukumay S, Agustino D, et al
Cash transfers to enhance completion of TB screening among household contacts in rural Tanzania.
Int J Tuberc Lung Dis. 2024;28:176-182.
PubMed Abstract available

MARKS SM, Winston CA
Estimated treatment costs for multidrug-resistant TB in the United States.
Int J Tuberc Lung Dis. 2024;28:214-215.
PubMed

KAWATSU L, Uchimura K, Schwalb A, Houben R, et al
New perspectives on the secular trend in pulmonary TB in post-war Japan (1953-1980).
Int J Tuberc Lung Dis. 2024;28:207-209.
PubMed

SHAIKH A, Sriraman K, Vaswani S, Shah I, et al
SMaRT-PCR: sampling using masks and RT-PCR, a non-invasive diagnostic tool for paediatric pulmonary TB.
Int J Tuberc Lung Dis. 2024;28:189-194.
PubMed Abstract available

March 2024

OTA M, Hirao S, Uchimura K
Lower TB notification rates in later life in the same birth cohort, Japan, 1950-2020.
Int J Tuberc Lung Dis. 2024;28:157-159.
PubMed

PONTALI E, Akkerman OW, Zenner D, Migliori GB, et al
Post-TB lung disease: keep going beyond TB!
Int J Tuberc Lung Dis. 2024;28:113-114.
PubMed

THEKKUR P, Thiagesan R, Nair D, Karunakaran N, et al
Using timeliness metrics for household contact tracing and TB preventive therapy in the private sector, India.
Int J Tuberc Lung Dis. 2024;28:122-139.
PubMed Abstract available

SOUSA S, Santos S, Alves CM, Goncalves G, et al
Impact of annual TB screening on stone quarry workers in high-incidence Portuguese municipalities.
Int J Tuberc Lung Dis. 2024;28:136-141.
PubMed Abstract available

THOMSON H, Baines N, Huisamen T, Koegelenberg CFN, et al
A new understanding of clinical patterns in post-TB lung disease.
Int J Tuberc Lung Dis. 2024;28:115-121.
PubMed Abstract available

LEVER S, Akkerman OW, Dekkers BGJ
Pancreatitis delays the absorption of first-line anti-TB drugs.
Int J Tuberc Lung Dis. 2024;28:163-165.
PubMed

YAMKOVOY K, Self JL, Jenkins HE, Horsburgh CR, et al
Patterns of TB transmission in the United States, 2011-2017.
Int J Tuberc Lung Dis. 2024;28:154-156.
PubMed

REZAEE M, Azizi N, Danaei B, Davari A, et al
TB and interstitial lung disease: a systematic review and meta-analysis.
Int J Tuberc Lung Dis. 2024;28:130-135.
PubMed Abstract available

RUDOLF F, Abate E, Moges B, Gomes VF, et al
A structured 2-week follow-up visit in the cascade of care for TB increases case detection.
Int J Tuberc Lung Dis. 2024;28:148-153.
PubMed Abstract available

LEAVITT SV, Rodriguez CA, Bouton TC, Horsburgh CR, et al
Outcomes for people with TB by disease severity at presentation.
Int J Tuberc Lung Dis. 2024;28:142-147.
PubMed Abstract available

February 2024

SILVA DR, Santos AP, Visca D, Bombarda S, et al
The potential for vaccines to aid the treatment of post-TB lung disease.
Int J Tuberc Lung Dis. 2024;28:44-45.
PubMed

LONG R, Heffernan C, Lau A
Emphasis on post-TB lung disease and other sequelae of TB is good but a public health approach to TB is morally ambitious???
Int J Tuberc Lung Dis. 2024;28:1-3.
PubMed

FEKADU G, Wang Y, You JHS
Cost-effectiveness of pretomanid-based regimen for highly drugresistant TB in a low-burden setting.
Int J Tuberc Lung Dis. 2024;28:12-17.
PubMed Abstract available

TURNER RD, Birring SS, Bothamley GH
Measuring cough-related quality of life and cough frequency in pulmonary TB.
Int J Tuberc Lung Dis. 2024;28:25-31.
PubMed Abstract available

SHIN JE, Jeon D, Mok J, Yim JJ, et al
Compliance with new drug use and the effect of discrepant drug susceptibility testing on MDR/RR-TB treatment.
Int J Tuberc Lung Dis. 2024;28:18-24.
PubMed Abstract available

DOLEZALOVA K, Kika V, Wallenfels J
Increasing incidence of TB in a low burden TB country due to migration from Ukraine.
Int J Tuberc Lung Dis. 2024;28:39-40.
PubMed

NIGHTINGALE ES, Feasey HRA, Khundi M, Soko RN, et al
Community-level variation in TB testing history in Blantyre, Malawi.
Int J Tuberc Lung Dis. 2024;28:32-38.
PubMed Abstract available

January 2024

YILDIRIM K, Bozkurt S, Basibuyuk HH, Coban AY, et al
Anti-tuberculosis activity of morusin: a promising flavonoid from white mulberry.
Int J Tuberc Lung Dis. 2024;28:37-41.
PubMed Abstract available

KUMAR SR, Hissar SS, Ramesh PM, Shanmugam M, et al
Ethambutol-induced optic neuropathy: should we mandate ophthalmic examination in TB treatment?
Int J Tuberc Lung Dis. 2024;28:51-53.
PubMed

SURIE D, Sathyanarayanan MK, Lavanya J, Smith JP, et al
Long-term follow-up of persons diagnosed with multidrug-resistant TB in Chennai, India, 2013-2020.
Int J Tuberc Lung Dis. 2024;28:54-56.
PubMed

RICCARDI N, Antonello RM, Besozzi G, Tadolini M, et al
Ten common myths about drug-susceptible TB.
Int J Tuberc Lung Dis. 2024;28:61-64.
PubMed

DU Y, Gu J, Yang Y, Chen Y, et al
Efficacy and safety of bicyclol for treating patients with antituberculosis drug-induced liver injury.
Int J Tuberc Lung Dis. 2024;28:6-12.
PubMed Abstract available

BEELER ASAY GR, Woodruff R, Sanderson DM, Fisher CF, et al
Cost-effectiveness of expanded latent TB infection testing and treatment: Lynn City, Massachusetts, USA.
Int J Tuberc Lung Dis. 2024;28:21-28.
PubMed Abstract available

SCHILDKRAUT JA, Sloan D, Boeree MJ
If you want to go far, go together: standardisation and data sharing in TB drug development.
Int J Tuberc Lung Dis. 2024;28:3-5.
PubMed

HOUBEN RMGJ, McCaffrey T, Tiemersma EW, Khan PY, et al
Estimating TB survival - mind the immortal-time gap.
Int J Tuberc Lung Dis. 2024;28:65-66.
PubMed

YUAN S, Cui Y, Shang Y, Su F, et al
Prevalence, temporal trends and risk factors of drug-resistant TB in Zibo, China, 2018-2021.
Int J Tuberc Lung Dis. 2024;28:57-58.
PubMed

GEIGER K, Patil A, Bergman A, Budhathoki C, et al
Exploring HIV disease indicators at MDR-TB treatment initiation in South Africa.
Int J Tuberc Lung Dis. 2024;28:42-50.
PubMed Abstract available

OLIVEIRA DA SILVA B, Salindri AD, Goncalves TO, Cunha EAT, et al
The impact of sputum quality on Xpert positivity in active case-finding for TB.
Int J Tuberc Lung Dis. 2024;28:29-36.
PubMed Abstract available

TYUFEKCHIEVA M, Varleva T
Monitoring TB infection in contact cases: the impact of the COVID-19 pandemic.
Int J Tuberc Lung Dis. 2024;28:59-60.
PubMed

December 2023

YANG H, Antwi S, Maranchick N, Dompreh A, et al
Effect of HIV infection on plasma exposure to first-line TB drugs and target attainment in children.
Int J Tuberc Lung Dis. 2023;27:931-937.
PubMed Abstract available

MAKEK MJ, Trauer JM, Blackbourn HD
Literature Highlights.
Int J Tuberc Lung Dis. 2023;27:882-884.
PubMed Abstract available

ARAUJO-PEREIRA M, Andrade BB
Atorvastatin to reduce bacillary load and attenuate lung damage in TB patients.
Int J Tuberc Lung Dis. 2023;27:880-881.
PubMed

COMMIESIE E, Stijnberg D, van den Boogaard J, Gopie F, et al
Challenges and opportunities for TB elimination in Suriname.
Int J Tuberc Lung Dis. 2023;27:946-948.
PubMed

RAGHEB SM, White JB, Jarand J, Fisher DA, et al
Assessing patient satisfaction with video-supported therapy for drug-susceptible TB treatment.
Int J Tuberc Lung Dis. 2023;27:938-940.
PubMed

CHUNG C, Jo KW, Shim TS
Treatment outcome, recurrence and safety of multidrug-resistant TB treated with low-dose linezolid.
Int J Tuberc Lung Dis. 2023;27:918-924.
PubMed Abstract available

DU CROS P, Greig J, Alffenaar JC, Cross GB, et al
Standards for clinical trials for treating TB.
Int J Tuberc Lung Dis. 2023;27:885-898.
PubMed Abstract available

ADEWOLE OO, Omotoso BA, Ogunsina M, Aminu A, et al
Atorvastatin improves sputum conversion and chest X-ray severity score.
Int J Tuberc Lung Dis. 2023;27:912-917.
PubMed Abstract available

QUINCER EM, Lyland A, Onyango D, LaCourse SM, et al
The effect of antenatal isoniazid preventive therapy on birth outcomes in Western Kenya.
Int J Tuberc Lung Dis. 2023;27:906-911.
PubMed Abstract available

NETO ERD, Matos TS, Ferreira ACF, Bezerra-Santos M, et al
The impact of COVID-19 on TB care in Brazil.
Int J Tuberc Lung Dis. 2023;27:941-943.
PubMed

MENDOZA-TICONA A, Mitnick CD, Obregon G, Alarcon V, et al
Screening with GenoType((R)) MTBDRplus shortens the time to MDR-TB treatment initiation but does not change outcomes.
Int J Tuberc Lung Dis. 2023;27:949-951.
PubMed

KIBIRIGE D, Andia-Biraro I, Olum R, Adakun S, et al
Metabolic characterisation of adult Ugandan patients with TB and diabetes mellitus comorbidity.
Int J Tuberc Lung Dis. 2023;27:944-945.
PubMed

November 2023

EDWARDS S, Humbert T, Berdzuli N, Azzopardi-Muscat N, et al
Tackling TB in Europe: treatment gaps and deteriorating treatment availability is undermining progress.
Int J Tuberc Lung Dis. 2023;27:793-796.
PubMed

MARGINEANU I, Butnaru T, Gafar F, Baiceanu D, et al
TB therapeutic drug monitoring - analysis of opportunities in Romania and Ukraine.
Int J Tuberc Lung Dis. 2023;27:816-821.
PubMed Abstract available

KATRAK S, Wang R, Barry P
Costs of treating multidrug-resistant TB in California in 2022.
Int J Tuberc Lung Dis. 2023;27:864-866.
PubMed

TANEJA R, Nahata MC, Scarim J, Pande PG, et al
A novel home-based method for preparing suspensions of anti-TB drugs.
Int J Tuberc Lung Dis. 2023;27:810-815.
PubMed Abstract available

INBARAJ LR, Rade K, Selvaraju S, Rao R, et al
Mortality estimates of central nervous system TB in India.
Int J Tuberc Lung Dis. 2023;27:876-877.
PubMed

FRITSCHI N, Vaezipour N, Buettcher M, Portevin D, et al
Ratios from full blood count as markers for TB diagnosis, treatment, prognosis: a systematic review.
Int J Tuberc Lung Dis. 2023;27:822-832.
PubMed Abstract available

October 2023

ANDREWS F, Welch S, Scandrett K, Kaur H, et al
Outcomes of TB contact tracing and predictors of success: a 10-year retrospective cohort analysis in Birmingham, UK.
Int J Tuberc Lung Dis. 2023;27:766-771.
PubMed Abstract available

TRAUER JM, Tiberi S, Graham SM, Blackbourn HD, et al
Literature Highlights.
Int J Tuberc Lung Dis. 2023;27:721-723.
PubMed Abstract available

NELSON KN, Shah NS, Cranmer LM, Vasudevan L, et al
An effective vaccine is only the first step: the need to create and sustain demand for TB vaccines.
Int J Tuberc Lung Dis. 2023;27:718-720.
PubMed

PUMA D, Geadas C, Calderon RI, Yuen CM, et al
Active case-finding for TB among incarcerated women in Peru.
Int J Tuberc Lung Dis. 2023;27:784-786.
PubMed

AKKERMAN OW, Dijkwel RDC, Kerstjens HAM, van der Werf TS, et al
Isoniazid and rifampicin exposure during treatment in drug-susceptible TB.
Int J Tuberc Lung Dis. 2023;27:772-777.
PubMed Abstract available

CHIANG SS, Zeng C, Roman-Sinche B, Altamirano E, et al
Adaptation and validation of a TB stigma scale for adolescents in Lima, Peru.
Int J Tuberc Lung Dis. 2023;27:754-760.
PubMed Abstract available

KIM JY, Koo B, Lim SY, Cha HH, et al
A non-invasive, sensitive assay for active TB: combined cell-free DNA detection and FluoroSpot assays.
Int J Tuberc Lung Dis. 2023;27:790-792.
PubMed

REKART ML, Aung A, Cullip T, Mulanda W, et al
Household drug-resistant TB contact tracing in Tajikistan.
Int J Tuberc Lung Dis. 2023;27:748-753.
PubMed Abstract available

RAJAVARDHANA T, Koushik MR, Jayakumar C, Ramalingam P, et al
Adherence to treatment on a daily-dose regimen for TB.
Int J Tuberc Lung Dis. 2023;27:778-780.
PubMed

SINGH UB, Ray Y, Kanswal S, Sharma HP, et al
Low rifampicin levels in plasma associated with a poor clinical response in patients with abdominal TB.
Int J Tuberc Lung Dis. 2023;27:787-789.
PubMed

FRAZIER C, Nabity SA, Flood J
Incidence of TB disease among persons who use drugs in California.
Int J Tuberc Lung Dis. 2023;27:781-783.
PubMed

RAJENDRAN P, Saini S, Kumar N, Vashistha H, et al
Establishing proof of concept for utility of Trueprep((R))-extracted DNA in line-probe assay testing.
Int J Tuberc Lung Dis. 2023;27:742-747.
PubMed Abstract available

September 2023

MACHAVARIANI E, Nonyane BAS, Lebina L, Mmolawa L, et al
Perceived stigma among people with TB and household contacts.
Int J Tuberc Lung Dis. 2023;27:675-681.
PubMed Abstract available

VILJOEN L, Acaba J, Agbassi YJP, Beko B, et al
Community perspective on child-friendly medications for drug-resistant TB: importance, priorities and advocacy.
Int J Tuberc Lung Dis. 2023;27:655-657.
PubMed

RODRIGUEZ CA, Leavitt SV, Bouton TC, Horsburgh CR, et al
Survival of people with untreated TB: effects of time, geography and setting.
Int J Tuberc Lung Dis. 2023;27:694-702.
PubMed Abstract available

BECKER GL, Amuge P, Ssebunya R, Motevalli M, et al
Predictors of mortality in Ugandan children with TB, 2016-2021.
Int J Tuberc Lung Dis. 2023;27:668-674.
PubMed Abstract available

DO NASCIMENTO DR, Serpa SF, Bezerra-Santos M, do Carmo RF, et al
The impact of the COVID-19 pandemic on TB diagnosis in the Brazilian prison population, 2020-2021.
Int J Tuberc Lung Dis. 2023;27:688-693.
PubMed Abstract available

GALEA JT, Chu AL, Sweetland AC, Jimenez J, et al
Latent TB and depressive symptoms in household contacts of persons with active TB.
Int J Tuberc Lung Dis. 2023;27:682-687.
PubMed Abstract available

August 2023

SILVA DR, Munoz-Torrico M, Fernandes GR, Narvaez-Diaz L, et al
Isoniazid-resistant TB: treatment outcomes and impact of regimens with fluoroquinolones.
Int J Tuberc Lung Dis. 2023;27:638-640.
PubMed

AHMED S, Lotia-Farrukh I, Khan PY, Adnan S, et al
High prevalence of multidrug-resistant TB among household contacts in a high burden setting.
Int J Tuberc Lung Dis. 2023;27:646-648.
PubMed

CHIANG SS, Graham SM, Schaaf HS, Marais BJ, et al
Clinical standards for drug-susceptible TB in children and adolescents.
Int J Tuberc Lung Dis. 2023;27:584-598.
PubMed Abstract available

MAKEK MJ, Amorim GGC, Ragonnet R, Blackbourn HD, et al
Literature Highlights.
Int J Tuberc Lung Dis. 2023;27:581-583.
PubMed Abstract available

ACUNA-VILLAORDUNA C, Jacobson KR, Horsburgh CR, Canning M, et al
Initial experience with BPaL-based regimens to treat multidrug-resistant TB.
Int J Tuberc Lung Dis. 2023;27:649-650.
PubMed

HACKER B, Breuer C, Priwitzer M, Otto-Knapp R, et al
TB screening of Ukrainian refugees in Germany.
Int J Tuberc Lung Dis. 2023;27:641-642.
PubMed

HONGPRASIT P, Sonthisombat P
Assessment of TB treatment adherence using computer-assisted self-interviewing.
Int J Tuberc Lung Dis. 2023;27:626-631.
PubMed Abstract available

RIKHOTSO MC, Ledwaba SE, Ngandu JK, Mavumengwana V, et al
Favourable outcomes in RR-TB patients using BPaL and other WHO-recommended second-line anti-TB drugs.
Int J Tuberc Lung Dis. 2023;27:599-605.
PubMed Abstract available

MARITZ ER, Montepiedra G, Mitchell CD, Madhi SA, et al
Predictors of TB disease in HIV-exposed children from Southern Africa.
Int J Tuberc Lung Dis. 2023;27:619-625.
PubMed Abstract available

CHIBOLELA M, de Haas P, Klinkenberg E, Kosloff B, et al
Use of stool swabs in molecular transport media increases access to Xpert Ultra testing for TB in children.
Int J Tuberc Lung Dis. 2023;27:612-618.
PubMed Abstract available

HABIB SS, Uzair M, Dhanwani A, Sohail K, et al
A model for integrating social protection measures with TB control in Pakistan.
Int J Tuberc Lung Dis. 2023;27:651-652.
PubMed

RACHOW A, Ivanova O, Bakuli A, Khosa C, et al
Performance of spirometry assessment at TB diagnosis.
Int J Tuberc Lung Dis. 2023;27:850-857.
PubMed Abstract available

SALERNO MM, Burzynski J, Mangan JM, Hill A, et al
Adverse events among persons with TB using in-person vs. electronic directly observed therapy.
Int J Tuberc Lung Dis. 2023;27:833-840.
PubMed Abstract available

OWOLABI OA, Sillah AK, Loum I, Touray A, et al
Factors associated with presenting to private sector care providers at the onset of TB symptoms.
Int J Tuberc Lung Dis. 2023;27:867-868.
PubMed

SILVESTRE CR, Cavaco M, Afonso R, Alves S, et al
TB infection in healthcare workers - the reality of a Portuguese hospital.
Int J Tuberc Lung Dis. 2023;27:874-875.
PubMed

CHO MM, Kim HW, Kim JS, Min J, et al
TB in ageing populations: lessons from Japan and Korea.
Int J Tuberc Lung Dis. 2023;27:869-871.
PubMed

July 2023

NUR N, Sharif AB, Mitra DK
Stress resilience in patients with drug-resistant TB.
Int J Tuberc Lung Dis. 2023;27:551-556.
PubMed Abstract available

OKOYA F, Huang CC, Zhang Z, Lecca L, et al
Culture-negative TB: clinical characteristics, risk factors and treatment outcomes.
Int J Tuberc Lung Dis. 2023;27:557-563.
PubMed Abstract available

ESCALANTE P, Vadiyala MR, Pathakumari B, Marty PK, et al
New diagnostics for the spectrum of asymptomatic TB: from infection to subclinical disease.
Int J Tuberc Lung Dis. 2023;27:499-505.
PubMed Abstract available

STRAUSS M, Wademan DT, Mcinziba A, Hoddinott G, et al
TB preventive therapy preferences among children and adolescents.
Int J Tuberc Lung Dis. 2023;27:520-529.
PubMed Abstract available

HARRIES AD, Lin Y, Thekkur P, Nair D, et al
Why TB programmes should assess for comorbidities, determinants and disability at the start and end of TB treatment.
Int J Tuberc Lung Dis. 2023;27:495-498.
PubMed

GLOGOWSKA A, Przybylski G, Bukowski J, Dolska E, et al
TB and COVID-19 co-infection in a pulmonology hospital.
Int J Tuberc Lung Dis. 2023;27:574-576.
PubMed

FERRARESE M, Antonello RM, Torri S, Saderi L, et al
Extrapulmonary TB: a 30-year observational study of an Italian cohort.
Int J Tuberc Lung Dis. 2023;27:564-566.
PubMed

WADEMAN DT, Viljoen L, Jacobs S, Meyerson K, et al
Children s priorities to improve the acceptability of MDR-TB treatment: qualitative data from South Africa.
Int J Tuberc Lung Dis. 2023;27:543-550.
PubMed Abstract available

SINGH KP, Carvalho ACC, Centis R, D Ambrosio L, et al
Clinical standards for the management of adverse effects during treatment for TB.
Int J Tuberc Lung Dis. 2023;27:506-519.
PubMed Abstract available

MARQUES J, Rocha JV, Soares P, Leite A, et al
The effect of TB patient delay on loss to follow-up in Portugal.
Int J Tuberc Lung Dis. 2023;27:537-542.
PubMed Abstract available

CENTENO HURTADO KT, Garcia Bohorquez DF, Ruiz Gonzalez CE, Masias Leon Y, et al
The burden of chronic obstructive pulmonary disease among hospitalised women in a developing country.
Int J Tuberc Lung Dis. 2023;27:530-536.
PubMed Abstract available

VENGURLEKAR D, Walker C, Mahajan R, Dalal A, et al
Linezolid resistance in patients with drug-resistant TB.
Int J Tuberc Lung Dis. 2023;27:567-569.
PubMed

ZUREIGAT H, Alhusban M, Nawaiseh M, Alomari L, et al
Steps towards TB elimination in Jordan.
Int J Tuberc Lung Dis. 2023;27:576-577.
PubMed

June 2023

DE VRIES G, Akkerman O, Boeree M, van Hest R, et al
Diagnosis, treatment and transmission of rifampicin-resistant TB in the Netherlands, 2010-2019.
Int J Tuberc Lung Dis. 2023;27:471-477.
PubMed Abstract available

MALHOTRA A, Mukiibi J, Kitonsa PJ, Nalutaaya A, et al
Higher yield using an event-based vs. door-to-door approach for active case-finding for TB.
Int J Tuberc Lung Dis. 2023;27:484-486.
PubMed

MAKEK MJ, Tiberi S, Felker I, Amorim GGC, et al
Literature Highlights.
Int J Tuberc Lung Dis. 2023;27:429-431.
PubMed Abstract available

NI N, Wang N, Veronese V, Wang MZ, et al
Current status and future prospects of TB digital treatment adherence technology use in China.
Int J Tuberc Lung Dis. 2023;27:438-443.
PubMed Abstract available

KIM SH, Yoo JY, Cho HS, Kim SR, et al
Clinical and imaging features of drug-susceptible and multidrug-resistant TB in Korean adults.
Int J Tuberc Lung Dis. 2023;27:487-489.
PubMed

LOUIE JK, Keh C, Agraz-Lara R, Phillips A, et al
Highlighting the characteristics of TB disease in older people.
Int J Tuberc Lung Dis. 2023;27:478-480.
PubMed

SUNG J, Musinguzi A, Kadota JL, Baik Y, et al
Understanding patient-level costs of weekly isoniazid-rifapentine (3HP) among people living with HIV in Uganda.
Int J Tuberc Lung Dis. 2023;27:458-464.
PubMed Abstract available

OESER C, Rangaka MX, Abubakar I
Digital approaches to reducing TB treatment loss to follow-up.
Int J Tuberc Lung Dis. 2023;27:432-437.
PubMed Abstract available

RICH ML, Khan U, Zeng C, LaHood A, et al
Outcomes of WHO-conforming, longer, all-oral multidrug-resistant TB regimens and analysis implications.
Int J Tuberc Lung Dis. 2023;27:451-457.
PubMed Abstract available

MYERS B, Carney T, Rooney J, Malatesta S, et al
Smoked drug use in patients with TB is associated with higher bacterial burden.
Int J Tuberc Lung Dis. 2023;27:444-450.
PubMed Abstract available

OTAALO B, Cevik M, Mwebesa E, Nabisere-Arinaitwe R, et al
Prevalence of COVID-19 infection in TB clinics in Kampala, Uganda.
Int J Tuberc Lung Dis. 2023;27:481-483.
PubMed

May 2023

GUNTHER G, Guglielmetti L, Leu C, van Leth F, et al
Relative cost of multidrug-resistant TB medicines in Europe.
Int J Tuberc Lung Dis. 2023;27:341-344.
PubMed

KWARA A, Yang H, Martyn-Dickens C, Enimil A, et al
Adequacy of WHO weight-band dosing and fixed-dose combinations for the treatment of TB in children.
Int J Tuberc Lung Dis. 2023;27:401-407.
PubMed Abstract available

GIRIDHARAN P, Devaleenal B, Thiruvengadam K, Kaleeswari M, et al
A novel method for contact tracing for TB at household and community level.
Int J Tuberc Lung Dis. 2023;27:414-415.
PubMed

SADERI L, Cabibbe AM, Puci M, Di Lorenzo B, et al
A systematic review of the costs of diagnosis for multidrug-resistant/extensively drug-resistant TB in different settings.
Int J Tuberc Lung Dis. 2023;27:348-356.
PubMed Abstract available

GERIC C, Qin ZZ, Denkinger CM, Kik SV, et al
The rise of artificial intelligence reading of chest X-rays for enhanced TB diagnosis and elimination.
Int J Tuberc Lung Dis. 2023;27:367-372.
PubMed Abstract available

FAJER EB, Costa FD, Pelissari DM, Diaz Quijano FA, et al
Use of rapid molecular TB diagnostics for incarcerated people in Brazil.
Int J Tuberc Lung Dis. 2023;27:416-418.
PubMed

KASWASWA K, Mlauzi L, Mpunga J, Mandambwe C, et al
Use of local data to evaluate TB contact investigation in Malawi.
Int J Tuberc Lung Dis. 2023;27:408-410.
PubMed

TANG J, Tang Z, Feng C, Tang Q, et al
Efficacy and safety of video-assisted thoracoscopic surgery for pulmonary TB.
Int J Tuberc Lung Dis. 2023;27:387-394.
PubMed Abstract available

MAUGANS C, Loveday M, Hlangu S, Waitt C, et al
Best practices for the care of pregnant people living with TB.
Int J Tuberc Lung Dis. 2023;27:357-366.
PubMed Abstract available

TAGUIBAO C, Lailo JM, Neukom J, Gones V, et al
Digital survey results on pharmacy access to fixed-dose combination drugs for TB in Indonesia.
Int J Tuberc Lung Dis. 2023;27:422-424.
PubMed

MOE S, Rekart ML, Hernandez D, Sholpan A, et al
Primary bedaquiline resistance in Karakalpakstan, Uzbekistan.
Int J Tuberc Lung Dis. 2023;27:381-386.
PubMed Abstract available

AHMED R, Osman N, Noory B, Osman R, et al
Prevalence and determinants of chronic respiratory diseases in adults in Sudan.
Int J Tuberc Lung Dis. 2023;27:373-380.
PubMed Abstract available

PAREDES JL, Picon V, Reynolds L, Ugarte-Gil C, et al
Impact of the COVID-19 pandemic on TB care in Peru.
Int J Tuberc Lung Dis. 2023;27:411-413.
PubMed

MUTEMBA CM, Schindele A, Munyangaju I, Ramanlal N, et al
Contribution of Xpert((R)) MTB/RIF to pediatric TB diagnosis in Mozambique.
Int J Tuberc Lung Dis. 2023;27:419-421.
PubMed

April 2023

GRIJOTA-CAMINO MD, Perez-Recio S, Trapero C, Luque MJ, et al
Identifying gaps in the cascade of care for latent TB infection in a low-incidence setting.
Int J Tuberc Lung Dis. 2023;27:315-321.
PubMed Abstract available

VELEN K, Nguyen TA, Pham CD, Le HT, et al
The effect of medication event reminder monitoring on treatment adherence of TB patients.
Int J Tuberc Lung Dis. 2023;27:322-328.
PubMed Abstract available

BOLHUIS MS, Akkerman OW, Sturkenboom MGG, van Boven JFM, et al
Bedaquiline exposure in people with drug-resistant TB treated for diabetes: analysis of two phase 2 trials.
Int J Tuberc Lung Dis. 2023;27:335-337.
PubMed

GOLETTI D, Pisapia R, Fusco FM, Aiello A, et al
Epidemiology, pathogenesis, clinical presentation and management of TB in patients with HIV and diabetes.
Int J Tuberc Lung Dis. 2023;27:284-290.
PubMed Abstract available

MIGLIORI GB, Blackbourn HD
Post-TB lung disease - the rationale for a Clinical Statement.
Int J Tuberc Lung Dis. 2023;27:243-244.
PubMed

CAMPBELL JR, Chan ED, Anderson LF, Bonnet M, et al
Association of smoking and alcohol use with rifampin-resistant TB treatment outcomes.
Int J Tuberc Lung Dis. 2023;27:338-340.
PubMed

SACHDEVA KS, Bhatnagar AK, Bhaskar A, Singla N, et al
QTc prolongation with bedaquiline treatment for drug-resistant pulmonary TB in a programmatic setting.
Int J Tuberc Lung Dis. 2023;27:329-331.
PubMed

KAZIBWE A, Kyazze AP, Ssekamatte P, Mutebi EI, et al
TB infection in adults with diabetes mellitus in Uganda.
Int J Tuberc Lung Dis. 2023;27:308-314.
PubMed Abstract available

NIGHTINGALE R, Carlin F, Meghji J, McMullen K, et al
Post-TB health and wellbeing.
Int J Tuberc Lung Dis. 2023;27:248-283.
PubMed Abstract available

MANGAN JM, Burzynski J, deCastro BR, Salerno MM, et al
Challenges associated with electronic and in-person directly observed therapy during a randomized trial.
Int J Tuberc Lung Dis. 2023;27:298-307.
PubMed Abstract available

KINTU TM, Mwanahamisi BS, Muwanguzi M, Kyagambiddwa T, et al
Unfavorable treatment outcomes among patients with drug-resistant TB in Uganda.
Int J Tuberc Lung Dis. 2023;27:291-297.
PubMed Abstract available

March 2023

COLA JP, Nascimento do Prado T, Alves KBA, Lapa E Silva JR, et al
Factors associated with non-completion of TB preventive treatment in Brazil.
Int J Tuberc Lung Dis. 2023;27:215-220.
PubMed Abstract available

HUDDART S, Asege L, Jaganath D, Golla M, et al
Continuous cough monitoring: a novel digital biomarker for TB diagnosis and treatment response monitoring.
Int J Tuberc Lung Dis. 2023;27:221-222.
PubMed

YAACOUB H, Farhat AM, Najjar-Pellet J, Zgheib J, et al
Planning for TB elimination in Lebanon.
Int J Tuberc Lung Dis. 2023;27:171-174.
PubMed

KWON YS, Jang JG, Lee J, Choi KJ, et al
Risk factors for peripheral neuropathy in patients on linezolid-containing regimens for drug-resistant TB.
Int J Tuberc Lung Dis. 2023;27:232-234.
PubMed

PALACIOS CF, Hough MA, Shrestha R, Moll AP, et al
Perceived stigma related to TB preventive therapy.
Int J Tuberc Lung Dis. 2023;27:209-214.
PubMed Abstract available

AKKERMAN OW, van Het Hof S, de Vries G, van Crevel R, et al
Characteristics and mortality of central nervous system TB in the Netherlands: a 15-year comparison with other forms of TB.
Int J Tuberc Lung Dis. 2023;27:237-239.
PubMed

HUAROTO L, Huaman MA, Mugruza R, Ticona C, et al
Active case-finding of pulmonary TB in an urban emergency department.
Int J Tuberc Lung Dis. 2023;27:202-208.
PubMed Abstract available

ADEWOLE OO, Omotoso BA, Ogunsina M, Aminu A, et al
Atorvastatin accelerates Mycobacterium tuberculosis clearance in pulmonary TB: a randomised phase IIA trial.
Int J Tuberc Lung Dis. 2023;27:226-228.
PubMed

MALIK AA, Jaswal M, Siddiqui S, Amanullah F, et al
Role of symptom and chest X-ray screening in evaluating child household contacts for pulmonary TB.
Int J Tuberc Lung Dis. 2023;27:235-236.
PubMed

TRAUER JM
Targeted TB control in migrants to low-burden countries.
Int J Tuberc Lung Dis. 2023;27:169-170.
PubMed

MARTINEZ-GARCIA MA, Guan WJ, de-la-Rosa D, Athanazio R, et al
Post-TB bronchiectasis: from pathogenesis to rehabilitation.
Int J Tuberc Lung Dis. 2023;27:175-181.
PubMed Abstract available

TANEJA R, Nahata MC, Scarim J, Pande PG, et al
Stable, compounded bedaquiline suspensions to support practical implementation of pediatric dosing in the field.
Int J Tuberc Lung Dis. 2023;27:189-194.
PubMed Abstract available

DAMARAJU V, Singh N, Garg M, Kathirvel S, et al
Effect of prior pulmonary TB on low-dose computed tomography during lung cancer screening.
Int J Tuberc Lung Dis. 2023;27:223-225.
PubMed

SPRUIJT I, Erkens C, Greenaway C, Mulder C, et al
Reducing the burden of TB among migrants to low TB incidence countries.
Int J Tuberc Lung Dis. 2023;27:182-188.
PubMed Abstract available

BAIK Y, Nakasolya O, Isooba D, Mukiibi J, et al
Cost to perform door-to-door universal sputum screening for TB in a high-burden community.
Int J Tuberc Lung Dis. 2023;27:195-201.
PubMed Abstract available

February 2023

CHUNG C, Shin JE, Jeon D, Kang H, et al
Treatment outcomes and safety of bedaquiline, delamanid, and linezolid in multidrug-resistant TB.
Int J Tuberc Lung Dis. 2023;27:151-153.
PubMed

GOMES I, Garg T, Churchyard G, Gupta A, et al
The cascade of care for household contacts of people with drug-resistant TB.
Int J Tuberc Lung Dis. 2023;27:154-156.
PubMed

TOCHAENG C, Eksombatchai D, Boonsarngsuk V
Factors associated with false-negative for T-SPOT.TB in patients with TB disease.
Int J Tuberc Lung Dis. 2023;27:128-134.
PubMed Abstract available

ALKABAB Y, Warkentin J, Cummins J, Katz B, et al
Therapeutic drug monitoring and TB treatment outcomes in patients with diabetes mellitus.
Int J Tuberc Lung Dis. 2023;27:135-139.
PubMed Abstract available

FORSMAN LD, Alffenaar JWC
Diabetes mellitus and TB - finding strategies to reduce the double burden of disease.
Int J Tuberc Lung Dis. 2023;27:91-93.
PubMed

BARKER M, Gunther A, Wurps H, Gebhardt A, et al
Ultrasound-guided lymph node biopsy in smear-negative children and adolescents with suspected TB.
Int J Tuberc Lung Dis. 2023;27:164-165.
PubMed

BOLSTERLI E, Keller PM, Suter-Riniker F, Kruger L, et al
A comparison of bronchoalveolar lavage and gastric aspirate for diagnosis of paediatric TB.
Int J Tuberc Lung Dis. 2023;27:148-150.
PubMed

VILLA S, Carugati M, Rubach MP, Cleaveland S, et al
'One Health approach to end zoonotic TB.
Int J Tuberc Lung Dis. 2023;27:101-105.
PubMed Abstract available

BALTAS I, Sturdy A, Kavallieros K, McGregor A, et al
Diabetes mellitus is not a predictor of poor TB treatment outcomes.
Int J Tuberc Lung Dis. 2023;27:140-145.
PubMed Abstract available

CHUKWUOGO O, Odume B, Ogbudebe C, Useni S, et al
Strategic approach to optimisation of TB contact investigation in Nigeria.
Int J Tuberc Lung Dis. 2023;27:161-163.
PubMed

PAUDEL K, Nalutaaya A, Robsky KO, Kitonsa PJ, et al
The impact of time at home on potential yield of home-based TB contact investigation.
Int J Tuberc Lung Dis. 2023;27:121-127.
PubMed Abstract available

KOESOEMADINATA RC, McAllister SM, Soetedjo NNM, Santoso P, et al
Diabetes characteristics and long-term management needs in diabetic TB patients.
Int J Tuberc Lung Dis. 2023;27:113-120.
PubMed Abstract available

TANEJA R, Nahata MC, Scarim J, Pande PG, et al
Extemporaneously compounded liquid formulations of clofazimine.
Int J Tuberc Lung Dis. 2023;27:106-112.
PubMed Abstract available

GENADE LP, Kahamba T, Scott L, Tempia S, et al
Co-testing a single sputum specimen for TB and SARS-CoV-2.
Int J Tuberc Lung Dis. 2023;27:146-147.
PubMed

January 2023

KHAN U, Guglielmetti L
Tailored TPT for drug-resistant TB - promoting equity and access to optimal care.
Int J Tuberc Lung Dis. 2023;27:89b-90.
PubMed

MANSOOR H, Hirani N, Chavan V, Das M, et al
Clinical utility of target-based next-generation sequencing for drug-resistant TB.
Int J Tuberc Lung Dis. 2023;27:41-48.
PubMed Abstract available

GILLESPIE SH
Improving outcomes for multidrug-resistant TB: the role of integrated systems.
Int J Tuberc Lung Dis. 2023;27:1-2.
PubMed

SEHGAL IS, Muthu V, Agarwal R
Aspergillus infection is an important complication of post-TB bronchiectasis.
Int J Tuberc Lung Dis. 2023;27:89a-89.
PubMed

OLARU ID, Beliz Meier M, Schumacher SG, Prodanovic N, et al
Co-administration of treatment for drug-resistant TB and hepatitis C.
Int J Tuberc Lung Dis. 2023;27:66-68.
PubMed

FELKER I, Trajman A
Shorter regimens for multidrug-/rifampicin-resistant TB.
Int J Tuberc Lung Dis. 2023;27:3-4.
PubMed

KWON YS, Shin JE, Kang H, Jeon D, et al
Treatment outcomes of multidrug-resistant TB with selective use of new drugs.
Int J Tuberc Lung Dis. 2023;27:55-60.
PubMed Abstract available

ZENG C, Mitnick CD, Hewison C, Bastard M, et al
Concordance of three approaches for operationalizing outcome definitions for multidrug-resistant TB.
Int J Tuberc Lung Dis. 2023;27:34-40.
PubMed Abstract available

CANTERA JL, Rashid AA, Lillis LM, Peck RB, et al
Isolation and purification of lipoarabinomannan from urine of adults with active TB.
Int J Tuberc Lung Dis. 2023;27:75-77.
PubMed

KNUDSEN S, Babu SP, Ramakrishnan J, Jenkins HE, et al
M. tuberculosis infection before, during and after pregnancy.
Int J Tuberc Lung Dis. 2023;27:72-74.
PubMed

ATSHEMYAN H, Khachatryan N, Manukyan A, Khachatryan A, et al
Implementation of modified, all-oral shorter TB regimens in Armenia.
Int J Tuberc Lung Dis. 2023;27:84-85.
PubMed

BUTOV D, Feshchenko Y, Chesov D, Myasoedov V, et al
National survey on the impact of the war in Ukraine on TB diagnostics and treatment services in 2022.
Int J Tuberc Lung Dis. 2023;27:86-88.
PubMed

TANEJA R, Nahata MC, Scarim J, Pande PG, et al
Sugar and sugar-free liquid formulations of delamanid for patients with rifampicin-resistant TB.
Int J Tuberc Lung Dis. 2023;27:13-18.
PubMed Abstract available

MAH JK, Lieu A, Fisher D, Lim RK, et al
Impact of the COVID-19 pandemic on the epidemiology of TB in a low-incidence setting.
Int J Tuberc Lung Dis. 2023;27:69-71.
PubMed

COX SR, Padmapriyadarsini C, Mave V, Seth B, et al
Characterising cause of death among people treated for drug-susceptible TB in India.
Int J Tuberc Lung Dis. 2023;27:78-80.
PubMed

JAW-TSAI S, Barry R, Pande PG, Taneja R, et al
Comparison of pharmacokinetics and bioavailability of bedaquiline fumarate, benzoate and maleate in dogs.
Int J Tuberc Lung Dis. 2023;27:28-33.
PubMed Abstract available

DE HAAS P, Nhung NV, Hng NT, Hoa NB, et al
Introduction of the Simple One-Step stool Xpert Ultra method to detect TB in children and adults.
Int J Tuberc Lung Dis. 2023;27:19-27.
PubMed Abstract available

December 2022

NOESKE J, Kuaban C
Tailored TB preventive treatment for drug-resistant TB - failing the test for appropriateness?
Int J Tuberc Lung Dis. 2022;26:1198.
PubMed

ALFFENAAR JWC, Marais BJ, Touw DJ
Paediatric formulations for the treatment of drug resistant TB: closing the gaps.
Int J Tuberc Lung Dis. 2022;26:1097-1100.
PubMed

IZUDI J, Sheira LA, Bajunirwe F, McCoy SI, et al
Effect of 6-month vs. 8-month regimen on retreatment success for pulmonary TB.
Int J Tuberc Lung Dis. 2022;26:1188-1190.
PubMed

DATTA A, Mohapatra PR, Bhuniya S, Mishra B, et al
TB treatment regimen for children: is a 4-month regimen really better than the 6-month regimen?
Int J Tuberc Lung Dis. 2022;26:1197.
PubMed

TANEJA R, Nahata MC, Scarim J, Pande PG, et al
Stable sugar and sugar-free suspensions of pretomanid.
Int J Tuberc Lung Dis. 2022;26:1112-1117.
PubMed Abstract available

DEVOID I, Sillah AK, Sutherland J, Owolabi O, et al
The household economic burden of drug-susceptible TB diagnosis and treatment in The Gambia.
Int J Tuberc Lung Dis. 2022;26:1162-1169.
PubMed Abstract available

MEMANI B, Furin J, Cox H, Reuter A, et al
A very sneaky bug: perspectives of front-line clinicians on whole-genome sequencing for drug-resistant TB.
Int J Tuberc Lung Dis. 2022;26:1180-1182.
PubMed

CARTER EJ, Mungai B, Njoroge T, Masese A, et al
Finding the missing children for TB care and prevention in Kenya.
Int J Tuberc Lung Dis. 2022;26:1144-1150.
PubMed Abstract available

November 2022

GRANOZZI B, Bisognin F, Tadolini M, Lombardi G, et al
IGRA test for TB in COVID-19: role of corticosteroids.
Int J Tuberc Lung Dis. 2022;26:1088-1091.
PubMed

SMITH-JEFFCOAT SE, Eisenach KD, Joloba M, Ssengooba W, et al
Quantification of multidrug-resistant M. tuberculosis bacilli in sputum during the first 8 weeks of treatment.
Int J Tuberc Lung Dis. 2022;26:1058-1064.
PubMed Abstract available

GARCIA-GOEZ JF, Tello-Cajiao ME, Vargas-Potes CJ, Penagos-Luna R, et al
Effect of biological therapies on TB treatment outcomes.
Int J Tuberc Lung Dis. 2022;26:1077-1079.
PubMed

DIEFENBACH-ELSTOB T, Rivest P, Benedetti A, Gordon C, et al
Patterns and characteristics of TB among key risk groups in Canada, 1993-2018.
Int J Tuberc Lung Dis. 2022;26:1041-1049.
PubMed Abstract available

VELAYUTHAM B, Shah V, Mythily V, Gopalaswamy R, et al
Factors influencing treatment outcomes in patients with isoniazid-resistant pulmonary TB.
Int J Tuberc Lung Dis. 2022;26:1033-1040.
PubMed Abstract available

WILLEMSTEIN IJM, de Vries G, Essink DR, Slump E, et al
TB in migrants residing in the Netherlands for at least 5 years at diagnosis, 2003-2018.
Int J Tuberc Lung Dis. 2022;26:1050-1057.
PubMed Abstract available

KRISHNAN N, Siddiqi K, Dogar O, Gabe R, et al
Predictors of long-term smoking abstinence in TB patients.
Int J Tuberc Lung Dis. 2022;26:1074-1076.
PubMed

BARRETT R, Creswell J, Sahu S, Qin ZZ, et al
User perspectives on the use of X-rays and computer-aided detection for TB.
Int J Tuberc Lung Dis. 2022;26:1083-1085.
PubMed

TRAORE M, Nguhiu P, Telly N, Traore S, et al
The high costs facing TB-affected households in Mali.
Int J Tuberc Lung Dis. 2022;26:1071-1073.
PubMed

October 2022

AIA P, Viney K, Kal M, Kisomb J, et al
The economic burden of TB faced by patients and affected families in Papua New Guinea.
Int J Tuberc Lung Dis. 2022;26:934-941.
PubMed Abstract available

MARAIS BJ, Bernays S, Schaaf HS, Fox GJ, et al
Increasing TB preventive treatment in children.
Int J Tuberc Lung Dis. 2022;26:903-905.
PubMed

TYEKU N, Apolisi I, Daniels J, Beko B, et al
Pediatric delamanid treatment for children with rifampicin-resistant TB.
Int J Tuberc Lung Dis. 2022;26:986-988.
PubMed

MENEZES D, Zenner D, Aldridge R, Anderson SR, et al
Country differences and determinants of yield in programmatic migrant TB screening in four European countries.
Int J Tuberc Lung Dis. 2022;26:942-948.
PubMed Abstract available

CATES L, Codreanu A, Ciobanu N, Fosburgh H, et al
Budget impact of next-generation sequencing for diagnosis of TB drug resistance in Moldova.
Int J Tuberc Lung Dis. 2022;26:963-969.
PubMed Abstract available

BLACKBOURN H, Tiberi S, Felker I
Literature Highlights.
Int J Tuberc Lung Dis. 2022;26:914-916.
PubMed Abstract available

PORRETTA AD, Manga S, Pontali E
TB care in prisons: the ongoing challenge.
Int J Tuberc Lung Dis. 2022;26:906-907.
PubMed

DIALLO A, Combary A, Bakyono R, Guene H, et al
A 2020 baseline assessment for the monitoring of the End TB indicator of catastrophic costs in Burkina Faso.
Int J Tuberc Lung Dis. 2022;26:970-977.
PubMed Abstract available

ROUZIER V, Murrill M, Kim S, Naini L, et al
Caregiver willingness to give TPT to children living with drug-resistant TB patients.
Int J Tuberc Lung Dis. 2022;26:949-955.
PubMed Abstract available

SCHWALB A, Emery JC, Houben RMGJ
Use of chest radiography screening for TB: a re-evaluation of the Kolin study.
Int J Tuberc Lung Dis. 2022;26:983-985.
PubMed

FATIMA R, Yaqoob A, Qadeer E, Khan MA, et al
Community- vs. hospital-based management of multidrug-resistant TB in Pakistan.
Int J Tuberc Lung Dis. 2022;26:929-933.
PubMed Abstract available

MANGOCHI P, Bossard C, Catacutan C, Van Laeken D, et al
TB screening, prevention and treatment cascade in a Malawi prison.
Int J Tuberc Lung Dis. 2022;26:956-962.
PubMed Abstract available

September 2022

FARIA N, Reis R
Screening for TB infection: the operator s impact.
Int J Tuberc Lung Dis. 2022;26:857-861.
PubMed Abstract available

MOHAPATRA PR, Mishra B, Dutta A, Bhuniya S, et al
Responding to WHO s 4-month regimen for drug-susceptible pulmonary TB.
Int J Tuberc Lung Dis. 2022;26:898-899.
PubMed

KHAN U, Guglielmetti L
Evidence and ethical considerations for the treatment of contacts exposed to drug-resistant TB.
Int J Tuberc Lung Dis. 2022;26:900-901.
PubMed

SABI I, Olomi W, Nkereuwem E, Togun T, et al
Diagnosis of paediatric TB using Xpert((R)) MTB/RIF Ultra on fresh respiratory samples.
Int J Tuberc Lung Dis. 2022;26:862-868.
PubMed Abstract available

SANTOS AP, Silva DR, Miranda G, Braga MS, et al
Xpert((R)) MTB/RIF Ultra: detection of extrapulmonary TB in a high-burden setting.
Int J Tuberc Lung Dis. 2022;26:880-882.
PubMed

DURET A, Olgemoeller F, Ferreras-Antolin L, Whittaker E, et al
Paediatric TB care in the United Kingdom.
Int J Tuberc Lung Dis. 2022;26:814-819.
PubMed Abstract available

SHUKLA A, Bromage S, Dholakia Y, Hemler EC, et al
Case-control study of vitamin D status and adult multidrug-resistant pulmonary TB.
Int J Tuberc Lung Dis. 2022;26:826-834.
PubMed Abstract available

CHO EJ, Kang MR, Kim JH, Lee JI, et al
Evaluation of the MolecuTech((R)) REBA MTB-XMDR kit for detection of pre-extensively drug-resistant TB.
Int J Tuberc Lung Dis. 2022;26:869-874.
PubMed Abstract available

SCHWALB A, Cachay R, Wright A, Phillips PPJ, et al
Factors associated with screening failure and study withdrawal in multidrug-resistant TB.
Int J Tuberc Lung Dis. 2022;26:820-825.
PubMed Abstract available

TABERNERO E, Rodrigo T, Garros J, Altube L, et al
TB in the elderly: clinical features and outcomes.
Int J Tuberc Lung Dis. 2022;26:842-849.
PubMed Abstract available

KRAEF C, Yedilbayev A, Seguy N, Bentzon A, et al
Uptake of the lateral flow urine LAM test in Europe and Central Asia.
Int J Tuberc Lung Dis. 2022;26:835-841.
PubMed Abstract available

August 2022

WEBER SF, Ruby LC, Heller T, Hande M, et al
TB disease patterns by HIV and diabetes status.
Int J Tuberc Lung Dis. 2022;26:733-740.
PubMed Abstract available

MALIK AA, Siddique M, Chandir S, Jaswal M, et al
Travel reimbursements, distance to health facility and preventive treatment cascade for drug-resistant TB.
Int J Tuberc Lung Dis. 2022;26:789-791.
PubMed

MAGOHE A, Kimario J, Lukmanji Z, Hendricks K, et al
Randomized, controlled trial of a protein-calorie supplement for women coinfected with HIV-TB.
Int J Tuberc Lung Dis. 2022;26:798-800.
PubMed

JASWAL M, Farooq S, Madhani F, Noorani S, et al
Implementing 3HP vs. IPT as TB preventive treatment in Pakistan.
Int J Tuberc Lung Dis. 2022;26:741-746.
PubMed Abstract available

CASALME DJO, Marcelo DB, Dela Cuesta DM, Tonquin M, et al
Feasibility and acceptability of asynchronous VOT among patients with MDR-TB.
Int J Tuberc Lung Dis. 2022;26:760-765.
PubMed Abstract available

CHHABRA S, Ong CWM, Sotgiu G
TB diagnosis and treatment during the COVID-19 pandemic.
Int J Tuberc Lung Dis. 2022;26:702-703.
PubMed

VERGEER SB, Oldenkamp R, Senkoro M, Mfinanga S, et al
Does distance to healthcare facility affect care-seeking for TB-related symptoms in Tanzania?
Int J Tuberc Lung Dis. 2022;26:747-752.
PubMed Abstract available

GEBRESELASSIE N, Falzon D, Zignol M, Viney K, et al
Bridging the gap: key evidence needed to strengthen global policies to end TB.
Int J Tuberc Lung Dis. 2022;26:704-707.
PubMed

NAQVI S, Cantu Y, Ong Uti S, Cavazos D, et al
Successes and challenges of latent TB screening and treatment in a high-prevalence US region.
Int J Tuberc Lung Dis. 2022;26:720-726.
PubMed Abstract available

KOKEBU DM, Ahmed S, Moodliar R, Chiang CY, et al
Failure or relapse predictors for the STREAM Stage 1 short regimen for RR-TB.
Int J Tuberc Lung Dis. 2022;26:753-759.
PubMed Abstract available

GIANNONI F, Lanni A, Iacobino A, Cirillo DM, et al
Decreasing trend of drug-resistant TB in Italy.
Int J Tuberc Lung Dis. 2022;26:775-783.
PubMed Abstract available

REKART ML, Morshed T, Mulanda WK, Klieascikova J, et al
Family directly observed therapy for children with drug-resistant TB.
Int J Tuberc Lung Dis. 2022;26:792-794.
PubMed

July 2022

ISMAIL F, Yousif A, Alfurjani M, Haq S, et al
TB in eastern Libya: a decreasing trend in recent decades.
Int J Tuberc Lung Dis. 2022;26:694-695.
PubMed

BASHAM CA, Orr PH
Monitoring TB program performance.
Int J Tuberc Lung Dis. 2022;26:692-693.
PubMed

NAIR P, Hasan T, Zaw KK, Allamuratova S, et al
Acquired bedaquiline resistance in Karakalpakstan, Uzbekistan.
Int J Tuberc Lung Dis. 2022;26:658-663.
PubMed Abstract available

CARVALHO ACC, Kritski AL
Community-based intervention and health education to scale up TB preventive treatment for children.
Int J Tuberc Lung Dis. 2022;26:587-589.
PubMed

AKKERMAN OW, Duarte R, Tiberi S, Schaaf HS, et al
Clinical standards for drug-susceptible pulmonary TB.
Int J Tuberc Lung Dis. 2022;26:592-604.
PubMed Abstract available

VAN DER WERF TS, Grobusch MP
Clinical standards for drug-susceptible TB: putting patients first.
Int J Tuberc Lung Dis. 2022;26:584-586.
PubMed

NGUENHA D, Acacio S, Murias-Closas A, Ramanlal N, et al
Prevalence and clinical characteristics of pulmonary TB among pregnant and post-partum women.
Int J Tuberc Lung Dis. 2022;26:641-649.
PubMed Abstract available

VARSHNEY K, Rusnak JC
TB reporting declines in priority countries during the COVID-19 pandemic.
Int J Tuberc Lung Dis. 2022;26:681-683.
PubMed

WEYENGA H, Onyango E, Katana AK, Pathmanathan I, et al
Trends in TB and HIV care and treatment cascade, Kenya, 2008-2018.
Int J Tuberc Lung Dis. 2022;26:623-628.
PubMed Abstract available

MIGLIORI GB, Tiberi S
WHO drug-resistant TB guidelines 2022: what is new?
Int J Tuberc Lung Dis. 2022;26:590-591.
PubMed

KAMBILI C, Rossenu S, Hoetelmans RMW, Birmingham E, et al
Addressing bedaquiline treatment interruptions in the treatment of drug-resistant TB.
Int J Tuberc Lung Dis. 2022;26:671-677.
PubMed Abstract available

June 2022

LAZARCHIK A, Nyaruhirira AU, Chiang CY, Wares F, et al
Global availability of susceptibility testing for second-line anti-tuberculosis agents.
Int J Tuberc Lung Dis. 2022;26:524-528.
PubMed Abstract available

PELZER PT, Smit Y, Tiemersma EW, Huong NT, et al
Does BCG vaccination protect against infection with M. tuberculosis?
Int J Tuberc Lung Dis. 2022;26:529-536.
PubMed Abstract available

SINHA P, Bhargava A, Carwile M, Cintron C, et al
Undernutrition can no longer be an afterthought for global efforts to eliminate TB.
Int J Tuberc Lung Dis. 2022;26:477-480.
PubMed

BOEKELHEIDE K, Olugbosi M, Nedelman J, Everitt D, et al
Male reproductive hormones in patients treated with pretomanid.
Int J Tuberc Lung Dis. 2022;26:558-565.
PubMed Abstract available

KANIGA K, Lounis N, Zhuo S, Bakare N, et al
Impact of Rv0678 mutations on patients with drug-resistant TB treated with bedaquiline.
Int J Tuberc Lung Dis. 2022;26:571-573.
PubMed

LAURSEN LL, Dahl VN, Wejse C
Stool testing for pulmonary TB diagnosis in adults.
Int J Tuberc Lung Dis. 2022;26:516-523.
PubMed Abstract available

SHIN AY, Jekarl DW, Kim HW, Ha JH, et al
Early line-probe assay using DNA specimens in patients with pulmonary TB.
Int J Tuberc Lung Dis. 2022;26:509-515.
PubMed Abstract available

NAUFAL F, Chaisson LH, Robsky KO, Delgado-Barroso P, et al
Number needed to screen for TB in clinical, structural or occupational risk groups.
Int J Tuberc Lung Dis. 2022;26:500-508.
PubMed Abstract available

MALIK AA, Amanullah F
Source case investigation can reduce the diagnostic gap for childhood TB.
Int J Tuberc Lung Dis. 2022;26:566-567.
PubMed

May 2022

GRANOZZI B, Bisognin F, Lombardi G, Dal Monte P, et al
TB mortality in low-incidence countries: can we reduce it further?
Int J Tuberc Lung Dis. 2022;26:467-469.
PubMed

GROSCHEL MI, van den Boom M, Dixit A, Skrahina A, et al
Management of childhood MDR-TB in Europe and Central Asia: report of a Regional WHO meeting.
Int J Tuberc Lung Dis. 2022;26:433-440.
PubMed Abstract available

SHAMPUTA IC, Nguyen DTK, Burdo T, Dao G, et al
Canadian immigrants awareness and perceptions of TB infection and TB.
Int J Tuberc Lung Dis. 2022;26:454-456.
PubMed

COOREY NJ, Kensitt L, Davies J, Keller E, et al
Risk factors for TB in Australia and their association with delayed treatment completion.
Int J Tuberc Lung Dis. 2022;26:399-405.
PubMed Abstract available

KRITSKI AL, Viveiros M, Carvalho ACC
Rapid molecular diagnostics to detect resistance to second-line anti-TB drugs.
Int J Tuberc Lung Dis. 2022;26:385-387.
PubMed

GANDHI R, Deepak KG, Verma G, Chaubey S, et al
Engaging private pharmacies to help end TB in India.
Int J Tuberc Lung Dis. 2022;26:457-459.
PubMed

NINAN MM, Rupali P, Varghese GM, Shalini EB, et al
Xpert Ultra in diagnosing extrapulmonary TB: accuracy and trace calls.
Int J Tuberc Lung Dis. 2022;26:441-445.
PubMed Abstract available

MALIK AA, Hussain H
Preventive treatment for MDR-TB exposure in households.
Int J Tuberc Lung Dis. 2022;26:466-467.
PubMed

CAPEDING TPJ, Rosa JD, Lam H, Gaviola DG, et al
Cost of TB prevention and treatment in the Philippines in 2017.
Int J Tuberc Lung Dis. 2022;26:392-398.
PubMed Abstract available

PALANI N, Premkumar M, Vaishnavee V, Dinesh V, et al
Trends in rifampicin and isoniazid resistance in patients with presumptive TB.
Int J Tuberc Lung Dis. 2022;26:446-453.
PubMed Abstract available

April 2022

MARCHESE V, Formenti B, Marchese L, Gregori N, et al
COVID-19 effect on TB presentation and outcome.
Int J Tuberc Lung Dis. 2022;26:375-377.
PubMed

KIM JW, Vella C, Parvez W, Verma R, et al
Impact of COVID-19 on the diagnosis and management of lung cancer and TB.
Int J Tuberc Lung Dis. 2022;26:372-374.
PubMed

ALLORANT A, Biswas S, Ahmed S, Wiens KE, et al
Finding gaps in routine TB surveillance activities in Bangladesh.
Int J Tuberc Lung Dis. 2022;26:356-362.
PubMed Abstract available

SHIVAKUMAR SVBY, Padmapriyadarsini C, Chavan A, Paradkar M, et al
Concomitant pulmonary disease is common among patients with extrapulmonary TB.
Int J Tuberc Lung Dis. 2022;26:341-347.
PubMed Abstract available

HUGHES G, Bern H, Chiang CY, Goodall RL, et al
QT prolongation in the STREAM Stage 1 Trial.
Int J Tuberc Lung Dis. 2022;26:334-340.
PubMed Abstract available

DEN BOON S, Lienhardt C, Zignol M, Schwartzman K, et al
WHO target product profiles for TB preventive treatment.
Int J Tuberc Lung Dis. 2022;26:302-309.
PubMed Abstract available

ADAMASHVILI N, Baliashvili D, Kuchukhidze G, Salindri AD, et al
Low BMI increases all-cause mortality rates in patients with drug-resistant TB.
Int J Tuberc Lung Dis. 2022;26:326-333.
PubMed Abstract available

PRADHAN NN, Paradkar MS, Kagal A, Valvi C, et al
Performance of Xpert((R)) MTB/RIF and Xpert((R)) Ultra for the diagnosis of tuberculous meningitis in children.
Int J Tuberc Lung Dis. 2022;26:317-325.
PubMed Abstract available

DOWDY DW, Islam MA
Finding TB s "missing millions", one district at a time.
Int J Tuberc Lung Dis. 2022;26:295.
PubMed

March 2022

SUMNER T, Jensen HT, Keogh-Brown MR, Vassall A, et al
Time to integrate epidemiological and economic models for TB.
Int J Tuberc Lung Dis. 2022;26:282-284.
PubMed

MBELELE PM, Sabiiti W, Heysell SK, Sauli E, et al
Use of a molecular bacterial load assay to distinguish between active TB and post-TB lung disease.
Int J Tuberc Lung Dis. 2022;26:276-278.
PubMed

MUSONDA HK, Rose PC, Switala J, Schaaf HS, et al
Paediatric admissions to a TB hospital: reasons for admission, clinical profile and outcomes.
Int J Tuberc Lung Dis. 2022;26:217-223.
PubMed Abstract available

MIGLIORI GB, Wu SJ, Matteelli A, Zenner D, et al
Clinical standards for the diagnosis, treatment and prevention of TB infection.
Int J Tuberc Lung Dis. 2022;26:190-205.
PubMed Abstract available

February 2022

TINOCO EM, Vasconcelos A, Alves F, Duarte R, et al
Impact of COVID-19 on extrapulmonary TB and the benefit of decentralised TB services.
Int J Tuberc Lung Dis. 2022;26:178-180.
PubMed

ORTIZ-MARTINEZ Y, Rodriguez-Morales AJ, Henao-Martinez AF
Decreased notification of TB cases during the COVID-19 pandemic.
Int J Tuberc Lung Dis. 2022;26:177-178.
PubMed

SCHIZA V, Kruse M, Xiao Y, Kar S, et al
Impact of the COVID-19 pandemic on TB infection testing.
Int J Tuberc Lung Dis. 2022;26:174-176.
PubMed

GUREVA T, Turkova A, Yablokova E, Smirnova P, et al
Fluoroquinolone preventive therapy for children exposed to MDR-TB.
Int J Tuberc Lung Dis. 2022;26:171-173.
PubMed

BOHLBRO AS, Patsche CB, Mendes AM, Sifna A, et al
A self-rated health score predicts severe disease and high mortality in patients with pulmonary TB.
Int J Tuberc Lung Dis. 2022;26:158-165.
PubMed Abstract available

MOHR-HOLLAND E, Daniels J, Reuter A, Rodriguez CA, et al
Early mortality during rifampicin-resistant TB treatment.
Int J Tuberc Lung Dis. 2022;26:150-157.
PubMed Abstract available

BEAUMONT AL, Doumbia A, Chateau N, Meynard JL, et al
Why are people still dying of drug-susceptible TB in Paris in the 21(st) century?
Int J Tuberc Lung Dis. 2022;26:142-149.
PubMed Abstract available

LOPEZ-VARELA E, Garcia-Prats AJ, Seddon JA, Draper HR, et al
Treatment outcomes and safety in children with rifampicin-resistant TB.
Int J Tuberc Lung Dis. 2022;26:133-141.
PubMed Abstract available

BURHAN E, Soepandi PZ, Isbaniah F, Damayanti K, et al
Determinants of treatment outcomes in patients with multidrug-resistant TB.
Int J Tuberc Lung Dis. 2022;26:126-132.
PubMed Abstract available

HOSSAIN MD, Rahim MA, Islam N, Afroze F, et al
TB prevalence among patients with diabetes in Bangladesh.
Int J Tuberc Lung Dis. 2022;26:119-125.
PubMed Abstract available

KHAWCHAROENPORN T, Noisang K
Incomplete contact investigation and risk of developing TB among healthcare professionals.
Int J Tuberc Lung Dis. 2022;26:111-118.
PubMed Abstract available

APRIANI L, Koesoemadinata RC, Bastos ML, Wulandari DA, et al
Implementing the 4R and 9H regimens for TB preventive treatment in Indonesia.
Int J Tuberc Lung Dis. 2022;26:103-110.
PubMed Abstract available

ILAIWY G, Heysell SK, Thomas TA
National approaches to TB care in adolescents.
Int J Tuberc Lung Dis. 2022;26:96-102.
PubMed Abstract available

SILVA DR, de Queiroz Mello FC
Improving outcomes for multidrug-resistant TB treatment.
Int J Tuberc Lung Dis. 2022;26:93-95.
PubMed

BARRETT J
Why are people still dying from TB in low-burden countries?
Int J Tuberc Lung Dis. 2022;26:91-92.
PubMed

HARRIES AD, Zellweger JP
Protecting healthcare workers from TB.
Int J Tuberc Lung Dis. 2022;26:89-90.
PubMed

GRAHAM SM, Amanullah F
Updated guidelines for child and adolescent TB.
Int J Tuberc Lung Dis. 2022;26:81-84.
PubMed

LANGE C, Kay A, Mandalakas AM
The need for effective drugs for TB prevention: set your goals high, and don t stop till you get there.
Int J Tuberc Lung Dis. 2022;26:85-88.
PubMed

January 2022

TADOLINI M, Onozaki I
National TB prevalence surveys in the COVID-19 era.
Int J Tuberc Lung Dis. 2022;26:4-5.
PubMed

SINHA P, White LF, Hochberg NS, Cegielski JP, et al
Avoiding pitfalls in calculating the population attributable fraction of undernutrition for TB.
Int J Tuberc Lung Dis. 2022;26:80.
PubMed

KLAOS K, Holicka Y, Groenheit R, Kodmon C, et al
Current state of national TB laboratory networks in Europe: achievements and challenges.
Int J Tuberc Lung Dis. 2022;26:71-73.
PubMed

OJUAWO O, Piracha S, Irshad S, Mirza M, et al
Tuberculous mastitis in a low-incidence setting: should respiratory physicians be concerned?
Int J Tuberc Lung Dis. 2022;26:69-70.
PubMed

PETRUCCIOLI E, Farroni C, Cuzzi G, Vanini V, et al
VIDAS((R)) TB-IGRA reagents induce a CD4(+) and CD8(+) T-cell IFN-gamma response for both TB infection and active TB.
Int J Tuberc Lung Dis. 2022;26:65-68.
PubMed

CHIPINDURO M, Timire C, Chirenda J, Matambo R, et al
TB prevalence in Zimbabwe: a national cross-sectional survey, 2014.
Int J Tuberc Lung Dis. 2022;26:57-64.
PubMed Abstract available

ACOSTA J, Flores P, Alarcon M, Grande-Ortiz M, et al
A randomised controlled trial to evaluate a medication monitoring system for TB treatment.
Int J Tuberc Lung Dis. 2022;26:44-49.
PubMed Abstract available

December 2021

ZAMANI S, Honarvar MR, Behnampour N, Sheikhy M, et al
Decline in TB incidence during the COVID-19 pandemic.
Int J Tuberc Lung Dis. 2021;25:1043-1044.
PubMed

SUMNER T, Fiore-Gartland A, Hatherill M, Houben RMGJ, et al
The effect of new Mycobacterium tuberculosis infection on the sensitivity of prognostic TB signatures.
Int J Tuberc Lung Dis. 2021;25:1001-1005.
PubMed Abstract available

SARDA R, Ray A
Pulmonary TB and chronic pulmonary aspergillosis.
Int J Tuberc Lung Dis. 2021;25:1042-1043.
PubMed

TESFAHUN H, Moussally K, Al-Ani NA, Al-Salhi LG, et al
Introduction of new drugs for drug-resistant TB in Iraq.
Int J Tuberc Lung Dis. 2021;25:1041-1042.
PubMed

CHATTERJEE S, Toshniwal MN, Bhide P, Sachdeva KS, et al
Costs of TB services in India (No 1).
Int J Tuberc Lung Dis. 2021;25:1013-1018.
PubMed Abstract available

ZHU H, Xie L, Liu ZQ, Wang B, et al
Population pharmacokinetics of bedaquiline in patients with drug-resistant TB.
Int J Tuberc Lung Dis. 2021;25:1006-1012.
PubMed Abstract available

NIKOLENKA A, Mansjo M, Skrahina A, Hurevich H, et al
Whole-genome sequencing differentiates relapse from re-infection in TB.
Int J Tuberc Lung Dis. 2021;25:995-1000.
PubMed Abstract available

LEE JJ, Kang HY, Lee WI, Cho SY, et al
Efflux pump gene expression study using RNA-seq in multidrug-resistant TB.
Int J Tuberc Lung Dis. 2021;25:974-981.
PubMed Abstract available

TELISINGHE L, Shaweno D, Hayes RJ, Dodd PJ, et al
The effect of systematic screening of the general population on TB case notification rates.
Int J Tuberc Lung Dis. 2021;25:964-973.
PubMed Abstract available

November 2021

ANTONY S, Bodhanwala M, Shah I
Clinical profile and outcomes of paediatric central nervous system tuberculomas.
Int J Tuberc Lung Dis. 2021;25:953-955.
PubMed

FUKUSHIMA K, Akagi K, Kondoh A, Kubo T, et al
Evaluation of QFT-Plus performance using blood samples stored at room temperature.
Int J Tuberc Lung Dis. 2021;25:948-949.
PubMed

WOLTERS BA, Aartsma Y, Jansen K, van Hest R, et al
Travel history and challenges of screening for latent TB infection in child asylum seekers.
Int J Tuberc Lung Dis. 2021;25:945-947.
PubMed

CHRISTOPHER DJ, Coelho V, Ebby GS, Shankar D, et al
Incremental yield of Xpert((R)) MTB/RIF Ultra over Xpert((R)) MTB/RIF in the diagnosis of extrapulmonary TB.
Int J Tuberc Lung Dis. 2021;25:939-944.
PubMed Abstract available

GATECHOMPOL S, Sophonphan J, Kerr SJ, Ubolyam S, et al
Monocyte-to-lymphocyte ratio as a predictor of TB among people living with HIV.
Int J Tuberc Lung Dis. 2021;25:933-938.
PubMed Abstract available

KASWA M, Minga G, Nkiere N, Mingiedi B, et al
The economic burden of TB-affected households in DR Congo.
Int J Tuberc Lung Dis. 2021;25:923-932.
PubMed Abstract available

STIEBER F, Howard J, Manissero D, Boyle J, et al
Evaluation of a lateral-flow nanoparticle fluorescence assay for TB infection diagnosis.
Int J Tuberc Lung Dis. 2021;25:917-922.
PubMed Abstract available

MURITHI W, Click ES, McCarthy KD, Okeyo E, et al
Need for caution when interpreting Xpert((R)) MTB/RIF results for rifampin resistance among children.
Int J Tuberc Lung Dis. 2021;25:911-916.
PubMed Abstract available

LUAN L, Fraisse P, Cordel H, Charlois C, et al
Screening for active and latent TB among migrants in France.
Int J Tuberc Lung Dis. 2021;25:903-910.
PubMed Abstract available

WINCKLER JL, Schaaf HS, Draper HR, McIlleron H, et al
Pharmacokinetics of high-dose isoniazid in children affected by multidrug-resistant TB.
Int J Tuberc Lung Dis. 2021;25:896-902.
PubMed Abstract available

TAAFFE J, Croda J, Moultrie H, Silva DS, et al
Advancing TB research using digitized programmatic data.
Int J Tuberc Lung Dis. 2021;25:890-895.
PubMed Abstract available

BOEREE MJ, Lange C, Thwaites G, Paton N, et al
UNITE4TB: a new consortium for clinical drug and regimen development for TB.
Int J Tuberc Lung Dis. 2021;25:886-889.
PubMed

OCHERETINA O, Brandao AP, Pang Y, Rodrigues C, et al
Impact of the bacillary load on the accuracy of rifampicin resistance results by Xpert((R)) MTB/RIF.
Int J Tuberc Lung Dis. 2021;25:881-885.
PubMed

ALFFENAAR JC, Marais BJ, Thomas TA
Is a high dose sufficient to achieve high isoniazid exposure in children affected by multidrug-resistant TB?
Int J Tuberc Lung Dis. 2021;25:879-880.
PubMed

October 2021

SEKANDI JN, Tucker EG, Zalwango S, Buregyeya E, et al
Digital technologies and loss to follow-up for TB patients.
Int J Tuberc Lung Dis. 2021;25:871-872.
PubMed

HASSAN L, Ali SM, Iqbal W, Baig S, et al
Automated detection and reduction of stigma in online discussions about TB.
Int J Tuberc Lung Dis. 2021;25:869-870.
PubMed

ARENAS-MIRAS M, Sanchez-Martinez F, Jove-Caballe N, Villar-Garcia J, et al
Clinical experience of TB in patients treated with anti-TNF-alpha.
Int J Tuberc Lung Dis. 2021;25:866-868.
PubMed

TAHSEEN S, Khanzada FM, Hussain A, Akhtar N, et al
Phenotypic vs. genotypic resistance to fluoroquinolones in rifampicin-resistant TB.
Int J Tuberc Lung Dis. 2021;25:861-863.
PubMed

EJO M, Van Deun A, Nunn A, Meredith S, et al
Effectiveness of GenoType MTBDRsl in excluding TB drug resistance in a clinical trial.
Int J Tuberc Lung Dis. 2021;25:839-845.
PubMed Abstract available

BLACK M, Da Silva P, Scott L
Rifampicin-resistant TB: discordance between Xpert((R)) MTB/RIF and MTBDRplus results.
Int J Tuberc Lung Dis. 2021;25:832-838.
PubMed Abstract available

OXLADE O, den Boon S, Menzies D, Falzon D, et al
TB preventive treatment in high- and intermediate-incidence countries: research needs for scale-up.
Int J Tuberc Lung Dis. 2021;25:823-831.
PubMed Abstract available

PURCHASE S, Batist E, Mmile N, Nkosi S, et al
Challenges in recruiting children to a multidrug-resistant TB prevention trial.
Int J Tuberc Lung Dis. 2021;25:814-822.
PubMed Abstract available

September 2021

KOZINSKA M, Podlasin R, Ropelewska-Lacka K, Wojtycha-Kwasnica B, et al
TB and COVID-19 coinfection.
Int J Tuberc Lung Dis. 2021;25:776-777.
PubMed

MOHR-HOLLAND E, Hacking D, Daniels J, Scott V, et al
Diagnosis patterns for rifampicin-resistant TB after onset of COVID-19.
Int J Tuberc Lung Dis. 2021;25:772-775.
PubMed

GIGANTE AR, Sousa M, Aguiar A, Pinto M, et al
The impact of COVID-19 on the TB response: data from the field.
Int J Tuberc Lung Dis. 2021;25:769-771.
PubMed

SHIN JE, Jo KW, O YJ, Jeon D, et al
Impact of revised definitions for extensively drug-resistant TB on disease classification.
Int J Tuberc Lung Dis. 2021;25:766-768.
PubMed

GUTIERREZ A, Isidro A, Herrerin J, Hinojosa J, et al
Meningeal TB in a mummified child from 4,000 years ago.
Int J Tuberc Lung Dis. 2021;25:761-762.
PubMed

KAMOLWAT P, Nonghanphithak D, Chaiprasert A, Smithtikarn S, et al
Diagnostic performance of whole-genome sequencing for identifying drug-resistant TB in Thailand.
Int J Tuberc Lung Dis. 2021;25:754-760.
PubMed Abstract available

HUDDART S, Ingawale P, Edwin J, Jondhale V, et al
TB case fatality and recurrence in a private sector cohort in Mumbai, India.
Int J Tuberc Lung Dis. 2021;25:738-746.
PubMed Abstract available

MOODLIAR R, Aksenova V, Frias MVG, van de Logt J, et al
Bedaquiline for multidrug-resistant TB in paediatric patients.
Int J Tuberc Lung Dis. 2021;25:716-724.
PubMed Abstract available

MURPHY RA, Douglas-Jones B, Mucinya G, Sunpath H, et al
Expanding the use of dolutegravir-based antiretroviral therapy in multidrug-resistant TB.
Int J Tuberc Lung Dis. 2021;25:696-700.
PubMed Abstract available

CHESOV D, Makhanda G, Furin J
Tackling the many layers of stigma is essential for the "End TB Strategy".
Int J Tuberc Lung Dis. 2021;25:683-684.
PubMed

August 2021

RANAIVOMANANA P, Knoblauch AM, Razafimahatratra MC, Raherinandrasana AH, et al
Pulmonary and pleural TB prevalence in pregnant women.
Int J Tuberc Lung Dis. 2021;25:668-670.
PubMed

EDDY JJ, Seth B, White LF, Sulis CA, et al
Decreasing time spent in airborne infection isolation during TB testing.
Int J Tuberc Lung Dis. 2021;25:665-667.
PubMed

CLARKSON MC, McQuaid CF, Houben RM, Kranzer K, et al
Better data for country-level TB resource allocation are urgently required.
Int J Tuberc Lung Dis. 2021;25:662-664.
PubMed

PERRY A, Chitnis A, Chin A, Hoffmann C, et al
Real-world implementation of video-observed therapy in an urban TB program in the United States.
Int J Tuberc Lung Dis. 2021;25:655-661.
PubMed Abstract available

SMITH AGC, Gujabidze M, Avaliani T, Blumberg HM, et al
Clinical outcomes among patients with tuberculous meningitis receiving intensified treatment regimens.
Int J Tuberc Lung Dis. 2021;25:632-639.
PubMed Abstract available

SHARMA K, Sharma M, Modi M, Singla N, et al
Comparative analysis of Truenat MTB Plus and Xpert((R)) Ultra in diagnosing tuberculous meningitis.
Int J Tuberc Lung Dis. 2021;25:626-631.
PubMed Abstract available

CAMPBELL JR, Katamba A, Oxlade O, Schwartzman K, et al
Improving country-level modelling to support TB prevention and care.
Int J Tuberc Lung Dis. 2021;25:607-608.
PubMed

DONOVAN J, Walker TM
Diagnosing tuberculous meningitis: a testing process.
Int J Tuberc Lung Dis. 2021;25:605-606.
PubMed

July 2021

AMOUR M, von Reyn CF
A new paradigm: testing household contacts of adolescents with incident TB infection.
Int J Tuberc Lung Dis. 2021;25:599b-600.
PubMed

RODRIGUEZ CA, Brooks MB, Aibana O, Mitnick CD, et al
Sputum culture conversion definitions and analytic practices for multidrug-resistant TB.
Int J Tuberc Lung Dis. 2021;25:596-598.
PubMed

ERISA KC, Robsky KO, Kitonsa PJ, Nalutaaya A, et al
Low prevalence of diabetes mellitus in TB patients and the community in urban Uganda.
Int J Tuberc Lung Dis. 2021;25:590-592.
PubMed

DOUGLAS-JONES B, Mohr-Holland E, Mema N, Mathee S, et al
A home-based care programme for rifampicin-resistant TB.
Int J Tuberc Lung Dis. 2021;25:587-589.
PubMed

HABIB SS, Malik AA, Khan U, Khowaja S, et al
Impact of upfront Xpert testing on time to treatment initiation for multidrug-resistant TB.
Int J Tuberc Lung Dis. 2021;25:584-586.
PubMed

MORAN A, Lebona L, Makgopa G, Nkwane Y, et al
One size does not fit all: reaching agricultural workers in South Africa with TB services.
Int J Tuberc Lung Dis. 2021;25:573-578.
PubMed Abstract available

YANGTHARA B, Wutthigate P, Roongmaitree S, Siripattanapipong P, et al
Nosocomial TB in two neonatal intensive care units at a tertiary care centre: infection risk and outcomes.
Int J Tuberc Lung Dis. 2021;25:567-572.
PubMed Abstract available

BLACK DA, McBrien SW, Gersh J, Ghassemieh B, et al
TB risk by time since U.S. entry among non-U.S.-born residents of Washington State, USA.
Int J Tuberc Lung Dis. 2021;25:560-566.
PubMed Abstract available

FEUTH T, Patovirta RL, Grierson S, Danilovits M, et al
Costs of multidrug-resistant TB treatment in Finland and Estonia affected by the 2019 WHO guidelines.
Int J Tuberc Lung Dis. 2021;25:554-559.
PubMed Abstract available

LARGEN A, Ayala A, Khurana R, Katz DJ, et al
Evaluation of point-of-care algorithms to detect diabetes during screening for latent TB infection.
Int J Tuberc Lung Dis. 2021;25:547-553.
PubMed Abstract available

BALUKU JB, Nuwagira E, Bongomin F, Denning DW, et al
Pulmonary TB and chronic pulmonary aspergillosis: clinical differences and similarities.
Int J Tuberc Lung Dis. 2021;25:537-546.
PubMed Abstract available

SHARMA M, Onozaki I, Nunn P
TB in older people in Asia: why it is important.
Int J Tuberc Lung Dis. 2021;25:521-524.
PubMed

SALZER HJF, Wang JY
Chronic pulmonary aspergillosis as a sequel to pulmonary TB.
Int J Tuberc Lung Dis. 2021;25:519-520.
PubMed

June 2021

AGOSTINIS A, Heffernan C, Long R, Beckon A, et al
Interferon-gamma release assays for latent tuberculosis infection screening in Canadian federal correctional facilities.
Int J Tuberc Lung Dis. 2021;25:447-452.
PubMed Abstract available

TEO AKJ, Ong CWM, Hsu LY
COVID-19 and TB: a progression-regression conundrum.
Int J Tuberc Lung Dis. 2021;25:421-423.
PubMed

BASHAM CA, Romanowski K, Johnston JC
Alcohol use disorder and TB survivor health.
Int J Tuberc Lung Dis. 2021;25:516-517.
PubMed

MANTSHONYANE L, Kgwaadira B, Gross R
The absence of evidence of cure is not a risk for recurrent TB among patients treated for TB.
Int J Tuberc Lung Dis. 2021;25:511-512.
PubMed

ROYCROFT E, Fitzgibbon MM, Kelly DM, Scully M, et al
The largest prison outbreak of TB in Western Europe investigated using whole-genome sequencing.
Int J Tuberc Lung Dis. 2021;25:491-497.
PubMed Abstract available

SZKWARKO D, Amisi JA, Peterson D, Burudi S, et al
Using a mobile application to improve pediatric presumptive TB identification in western Kenya.
Int J Tuberc Lung Dis. 2021;25:468-474.
PubMed Abstract available

REDWOOD L, Mitchell EMH, Viney K, Snow K, et al
Depression, stigma and quality of life in people with drug-susceptible TB and drug-resistant TB in Vietnam.
Int J Tuberc Lung Dis. 2021;25:461-467.
PubMed Abstract available

OELOFSE S, Esmail A, Diacon AH, Conradie F, et al
Pretomanid with bedaquiline and linezolid for drug-resistant TB: a comparison of prospective cohorts.
Int J Tuberc Lung Dis. 2021;25:453-460.
PubMed Abstract available

CHAISSON LH, Naufal F, Delgado-Barroso P, Alvarez-Manzo HS, et al
A systematic review of the number needed to screen for active TB among people living with HIV.
Int J Tuberc Lung Dis. 2021;25:427-435.
PubMed Abstract available

TAVOSCHI L, Toscanini F, Pontali E
TB and prisons: confinement does not contain the disease.
Int J Tuberc Lung Dis. 2021;25:424-426.
PubMed

AKKERMAN OW, Tiberi S, Alffenaar JW
Shortening MDR-TB treatment: is treating more patients with fewer drugs better?
Int J Tuberc Lung Dis. 2021;25:419-420.
PubMed

May 2021

ZOKUFA N, Lebelo K, Hacking D, Tabo L, et al
Community-based TB testing as an essential part of TB recovery plans in the COVID-19 era.
Int J Tuberc Lung Dis. 2021;25:406-408.
PubMed

POLLOCK NR, MacIntyre AT, Blauwkamp TA, Blair L, et al
Detection of Mycobacterium tuberculosis cell-free DNA to diagnose TB in pediatric and adult patients.
Int J Tuberc Lung Dis. 2021;25:403-405.
PubMed

MIN J, Kang JY, Kim J, Yang J, et al
Impact of COVID-19 on TB services in Korea.
Int J Tuberc Lung Dis. 2021;25:400-402.
PubMed

MARGINEANU I, Mor Z, Garcia D, Gilpin C, et al
TB and COVID-19 in migrants - the need to focus on both conditions.
Int J Tuberc Lung Dis. 2021;25:333-335.
PubMed

MCQUAID CF, Foster N, Quaife M, Levy J, et al
Digital adherence technology for TB: focus on livelihoods as well as lives.
Int J Tuberc Lung Dis. 2021;25:416-417.
PubMed

RICCARDI N, Saderi L, Borroni E, Tagliani E, et al
Therapeutic strategies and outcomes of MDR and pre-XDR-TB in Italy: a nationwide study.
Int J Tuberc Lung Dis. 2021;25:395-399.
PubMed Abstract available

KALEMA N, Semeere A, Banturaki G, Kyamugabwa A, et al
Gaps in TB preventive therapy for persons initiating antiretroviral therapy in Uganda: an explanatory sequential cascade analysis.
Int J Tuberc Lung Dis. 2021;25:388-394.
PubMed Abstract available

SATYANARAYANA S, Bhatia V, Mandal PP, Kanchar A, et al
Urgent need to address the slow scale-up of TB preventive treatment in the WHO South-East Asia Region.
Int J Tuberc Lung Dis. 2021;25:382-387.
PubMed Abstract available

FERREIRO L, Ruano-Ravina A, Otero-Mallo R, Pou-Alvarez C, et al
Recent epidemiological trends in extrapulmonary TB in Galicia, Spain.
Int J Tuberc Lung Dis. 2021;25:373-381.
PubMed Abstract available

WEYENGA H, Karanja M, Onyango E, Katana AK, et al
Can isoniazid preventive therapy be scaled up rapidly? Lessons learned in Kenya, 2014-2018.
Int J Tuberc Lung Dis. 2021;25:367-372.
PubMed Abstract available

MARTSON AG, Kim HY, Marais B, Alffenaar JW, et al
The importance of pharmacokinetics/pharmacodynamics assessment in Phase IIB/III trials for MDR-TB treatment.
Int J Tuberc Lung Dis. 2021;25:336-339.
PubMed

April 2021

MALABAD JCM, Ang CF, Palabrica FAR, Cajucom MAM, et al
Molecular epidemiology of Mycobacterium tuberculosis in adult Filipino TB-HIV co-infected patients.
Int J Tuberc Lung Dis. 2021;25:285-291.
PubMed Abstract available

HARRIES AD, Kumar AMV, Satyanarayana S, Thekkur P, et al
TB and COVID-19: measuring key risk factors that affect treatment outcomes.
Int J Tuberc Lung Dis. 2021;25:329-331.
PubMed

COX V, Guglielmetti L, Hewison C, Reuter A, et al
Reply to: "Human rights: finding the right balance for rifampicin-resistant TB treatment".
Int J Tuberc Lung Dis. 2021;25:328-329.
PubMed

VAN DEUN A, Piubello A, Lynen L, de Jong BC, et al
Human rights: finding the right balance for rifampicin-resistant TB treatment.
Int J Tuberc Lung Dis. 2021;25:327-328.
PubMed

GULLON-BLANCO JA, Rodrigo-Sanz T, Alvarez-Navascues F, Tabernero-Huguet E, et al
Completion of treatment for latent TB infection in a low prevalence setting.
Int J Tuberc Lung Dis. 2021;25:321-323.
PubMed

ROY N, Krishnamoorthy Y, Rajaa S, Ezhumalai K, et al
Health-related quality of life and its effect on TB treatment outcomes.
Int J Tuberc Lung Dis. 2021;25:318-320.
PubMed

BHERING M, Duarte R, Kritski A
Treatment outcomes and predictive factors for multidrug-resistant TB and HIV coinfection in Rio de Janeiro State, Brazil.
Int J Tuberc Lung Dis. 2021;25:292-298.
PubMed Abstract available

CHESOV D, Butov D, Reimann M, Heyckendorf J, et al
Impact of lung function on treatment outcome in patients with TB.
Int J Tuberc Lung Dis. 2021;25:277-284.
PubMed Abstract available

VISCA D, D Ambrosio L, Centis R, Pontali E, et al
Post-TB disease: a new topic for investigation-and why it matters.
Int J Tuberc Lung Dis. 2021;25:258-261.
PubMed

LAU A, Ferrara G
Disseminated TB: still being missed and misunderstood.
Int J Tuberc Lung Dis. 2021;25:255-257.
PubMed

SCHULTINK MP, Kerstjens HAM, Ter Beek L, Zondag H, et al
Assessment of TB treatment on patient well-being.
Int J Tuberc Lung Dis. 2021;25:315-317.
PubMed

March 2021

KUMAR MS, Surendran D, Manu MS, Rakesh PS, et al
Mortality due to TB-COVID-19 coinfection in India.
Int J Tuberc Lung Dis. 2021;25:250-251.
PubMed

GRACIAA DS, Kempker RR, Sanikidze E, Tukvadze S, et al
TB research amidst the COVID-19 pandemic.
Int J Tuberc Lung Dis. 2021;25:167-170.
PubMed

ALLWOOD BW, van der Zalm MM, Mortimer K
Reply to "Clinical care for patients with post TB lung disease".
Int J Tuberc Lung Dis. 2021;25:253-254.
PubMed

GUNTHER G, Ithete S
Clinical care for patients with post-TB lung disease.
Int J Tuberc Lung Dis. 2021;25:252-253.
PubMed

PARK JH, Jung J, Kim JY, Hong MJ, et al
Airborne precautions based on Xpert((R)) MTB/RIF results for patients with presumptive TB.
Int J Tuberc Lung Dis. 2021;25:244-246.
PubMed

KIZNY GORDON A, Tong SYC, Martinez E, Crighton T, et al
TB genomic surveillance and data sharing in recognising contamination events.
Int J Tuberc Lung Dis. 2021;25:241-243.
PubMed

BAIK Y, Nalutaaya A, Kitonsa PJ, Dowdy DW, et al
Infection status of contacts is not associated with severity of TB in the index case.
Int J Tuberc Lung Dis. 2021;25:237-240.
PubMed

ADANKWAH E, Arthur RA, Minadzi D, Owusu DO, et al
Immune response against TB and non-tuberculous mycobacterial pulmonary disease.
Int J Tuberc Lung Dis. 2021;25:234-236.
PubMed

MALIK AA, Fuad J, Abbass W, Ikhlaque S, et al
Preventive treatment of drug-resistant TB in a rural setting.
Int J Tuberc Lung Dis. 2021;25:231-233.
PubMed

CATES L, Crudu V, Codreanu A, Ciobanu N, et al
Laboratory costs of diagnosing TB in a high multidrug-resistant TB setting.
Int J Tuberc Lung Dis. 2021;25:228-230.
PubMed

COX SR, Gupte AN, Thomas B, Gaikwad S, et al
Unhealthy alcohol use independently associated with unfavorable TB treatment outcomes among Indian men.
Int J Tuberc Lung Dis. 2021;25:182-190.
PubMed Abstract available

SOHN H, Sweeney S, Mudzengi D, Creswell J, et al
Determining the value of TB active case-finding: current evidence and methodological considerations.
Int J Tuberc Lung Dis. 2021;25:171-181.
PubMed Abstract available

February 2021

BARRETT J, Painter H, Rajgopal A, Keane D, et al
Increase in disseminated TB during the COVID-19 pandemic.
Int J Tuberc Lung Dis. 2021;25:160-166.
PubMed

ALLWOOD BW, van der Zalm MM, Mortimer K
Reply to: Taking action to improve post-TB lung health.
Int J Tuberc Lung Dis. 2021;25:163a-163.
PubMed

HARRIES AD, Dlodlo RA, Brigden G, Chakaya JM, et al
Taking action to improve post-TB lung health.
Int J Tuberc Lung Dis. 2021;25:161-162.
PubMed

MOLINA-MOYA B, Guglielmetti L, Bothamley G, van Leth F, et al
Use and impact of molecular methods for detecting drug-resistant TB.
Int J Tuberc Lung Dis. 2021;25:157-159.
PubMed

LAW WS, Chan CKA, Leung CC
Management of latent TB infection in child household contacts aged under 5 years.
Int J Tuberc Lung Dis. 2021;25:151-153.
PubMed

MEHTA SN, Murrill M, Suryavanshi N, Bhosale R, et al
TB-related knowledge and stigma among pregnant women in low-resource settings.
Int J Tuberc Lung Dis. 2021;25:148-150.
PubMed

ARSCOTT-MILLS T, Ejelonu A, Mokalane K, Machao G, et al
One third of child TB cases were missing from the national TB register in Botswana.
Int J Tuberc Lung Dis. 2021;25:142-144.
PubMed

DE VOS E, Scott L, Voss De Lima Y, Warren RM, et al
Management of rifampicin-resistant TB: programme indicators and care cascade analysis in South Africa.
Int J Tuberc Lung Dis. 2021;25:134-141.
PubMed Abstract available

SOTGIU G, Rosales-Klintz S, Centis R, D'Ambrosio L, et al
TB management in the European Union/European Economic Area: a multi-centre survey.
Int J Tuberc Lung Dis. 2021;25:126-133.
PubMed Abstract available

FOX GJ, Johnston JC, Nguyen TA, Majumdar SS, et al
Active case-finding in contacts of people with TB.
Int J Tuberc Lung Dis. 2021;25:95-105.
PubMed Abstract available

LINH NN, Miller C, Marks GB
Potential benefits of active case finding to reduce the burden of TB.
Int J Tuberc Lung Dis. 2021;25:93-94.
PubMed

January 2021

SHEN X, Sha W, Yang C, Pan Q, et al
Continuity of TB services during the COVID-19 pandemic in China.
Int J Tuberc Lung Dis. 2021;25:81-83.
PubMed

TB and COVID-19 co-infection: rationale and aims of a global study.
Int J Tuberc Lung Dis. 2021;25:78-80.
PubMed

MAUG AKJ, Hossain MA, Gumusboga M, Decroo T, et al
Finding the right balance between efficacy and tolerability for TB treatment: the search continues.
Int J Tuberc Lung Dis. 2021;25:84-86.
PubMed

PARIGI S, Venturini E, Galli L, Chiappini E, et al
Xpert((R)) MTB/RIF Ultra performance in diagnosing paediatric pulmonary TB in gastric aspirates.
Int J Tuberc Lung Dis. 2021;25:75-77.
PubMed

SAKR CJ, Musharrafieh UM, Banna HS, Hoteit RA, et al
Risks and benefits of QuantiFERON((R))-TB testing for LTBI screening of health workers.
Int J Tuberc Lung Dis. 2021;25:72-74.
PubMed

GENDERINI FG, Dauby N, Delforge M, De Wit S, et al
TB in the intensive care unit in a low-endemic country.
Int J Tuberc Lung Dis. 2021;25:69-71.
PubMed

NABISERE R, Arinaitwe A, Muyise R, Asienzo J, et al
Implementation of TB preventive therapy in Uganda: effect of an intervention on completion rates.
Int J Tuberc Lung Dis. 2021;25:64-65.
PubMed

TUCKER A, Oyuku D, Nalugwa T, Nantale M, et al
Costs along the TB diagnostic pathway in Uganda.
Int J Tuberc Lung Dis. 2021;25:61-63.
PubMed

MAVE V, Kadam D, Gaikwad S, Kinikar A, et al
Measuring TB drug levels in the hair in adults and children to monitor drug exposure and outcomes.
Int J Tuberc Lung Dis. 2021;25:52-60.
PubMed Abstract available

MESFIN AB, Araia ZZ, Beyene HN, Mebrahtu AH, et al
First molecular-based anti-TB drug resistance survey in Eritrea.
Int J Tuberc Lung Dis. 2021;25:43-51.
PubMed Abstract available

SENEADZA NAH, Antwi S, Yang H, Enimil A, et al
Effect of malnutrition on the pharmacokinetics of anti-TB drugs in Ghanaian children.
Int J Tuberc Lung Dis. 2021;25:36-42.
PubMed Abstract available

WROHAN I, Redwood L, Ho J, Velen K, et al
Ototoxicity among multidrug-resistant TB patients: a systematic review and meta-analysis.
Int J Tuberc Lung Dis. 2021;25:23-30.
PubMed Abstract available

SOH AZ, Tan CTY, Mok E, Chee CBE, et al
Adipokines and the risk of active TB: a nested case-control study.
Int J Tuberc Lung Dis. 2021;25:31-35.
PubMed Abstract available

December 2020

ZHANG H, Cao X, Wang D, Xin H, et al
The acquisition of Mycobacterium tuberculosis infection in village doctors in China: a prospective study.
Int J Tuberc Lung Dis. 2020;24:1241-1246.
PubMed Abstract available

FANG JL, Chao CM, Tang HJ
The impact of COVID-19 on the diagnosis of TB in Taiwan.
Int J Tuberc Lung Dis. 2020;24:1321-1322.
PubMed

SINGH J, Ehtesham NZ, Hasnain SE
Two parallel pandemics: the challenges faced by countries with COVID-19 and TB.
Int J Tuberc Lung Dis. 2020;24:1319-1320.
PubMed

November 2020

FATIMA R, Yaqoob A
In Reply: How TB and COVID-19 compare: an opportunity to integrate both control programmes.
Int J Tuberc Lung Dis. 2020;24:1227-1228.
PubMed

DE SOUZA CDF, Coutinho HS, Costa MM, Magalhaes MAFM, et al
Impact of COVID-19 on TB diagnosis in Northeastern Brazil.
Int J Tuberc Lung Dis. 2020;24:1220-1222.
PubMed

ZHOU S, Van Staden Q, Toska E
Resource reprioritisation amid competing health risks for TB and COVID-19.
Int J Tuberc Lung Dis. 2020;24:1215-1216.
PubMed

KADOTA JL, Reza TF, Nalugwa T, Kityamuwesi A, et al
Impact of shelter-in-place on TB case notifications and mortality during the COVID-19 pandemic.
Int J Tuberc Lung Dis. 2020;24:1212-1214.
PubMed

HAAS MK, Ignatius EH, Stout JE, Dooley KE, et al
Finding the right balance between efficacy and tolerability for TB treatment.
Int J Tuberc Lung Dis. 2020;24:1225b-1226.
PubMed

WANG EY, Ahluwalia IB, Mase SR
Response to Correspondence: The impact of smoking on TB treatment outcomes includes recurrent TB.
Int J Tuberc Lung Dis. 2020;24:1225a-1225.
PubMed

DHAMGAYE TM
In reply: Latent TB treatment in pregnant women: a patient perspective.
Int J Tuberc Lung Dis. 2020;24:1226-1227.
PubMed

CHIANG CY, Bam TS
The impact of smoking on TB treatment outcomes includes recurrent TB.
Int J Tuberc Lung Dis. 2020;24:1224-1225.
PubMed

October 2020

KIM HW, Min J, Shin AY, Koo HK, et al
Reasons why patients with tuberculosis in South Korea stop anti-TB treatment: a cross-sectional study.
Int J Tuberc Lung Dis. 2020;24:1016-1023.
PubMed Abstract available

SHAHRIARIRAD R, Fallahi MJ
TB and the COVID-19 pandemic: brothers in arms against lung health.
Int J Tuberc Lung Dis. 2020;24:1126-1127.
PubMed

WU Z, Chen J, Xia Z, Pan Q, et al
Impact of the COVID-19 pandemic on the detection of TB in Shanghai, China.
Int J Tuberc Lung Dis. 2020;24:1122-1124.
PubMed

MENEGUIM AC, Rebello L, Das M, Ravi S, et al
Adapting TB services during the COVID-19 pandemic in Mumbai, India.
Int J Tuberc Lung Dis. 2020;24:1119-1121.
PubMed

HELDAL E, Dlodlo RA
Estimating subnational TB burden-why not strengthen and use routine recording and reporting?
Int J Tuberc Lung Dis. 2020;24:1125-1127.
PubMed

AKKERMAN OW, Tiberi S
The importance of knowing why TB patients stop anti-TB treatment.
Int J Tuberc Lung Dis. 2020;24:989-990.
PubMed

September 2020

YASSIN M, Grzemska M
Response to 'The Green Light Committee could contribute to ending tuberculosis .
Int J Tuberc Lung Dis. 2020;24:984.
PubMed

NGUYEN TBP, Nguyen TA, Luu BK, Le TTO, et al
A comparison of digital chest radiography and Xpert((R)) MTB/RIF in active case finding for tuberculosis.
Int J Tuberc Lung Dis. 2020;24:934-940.
PubMed Abstract available

CHIANG CH, Lee GH, Chiang TH, Tang PU, et al
Disseminated Mycobacterium avium complex infection as a differential diagnosis of tuberculosis in HIV patients.
Int J Tuberc Lung Dis. 2020;24:922-927.
PubMed Abstract available

LOVEDAY M, Hlangu S, Furin J
Breastfeeding in women living with tuberculosis.
Int J Tuberc Lung Dis. 2020;24:880-891.
PubMed Abstract available

ADEWOLE OO
Impact of COVID-19 on TB care: experiences of a treatment centre in Nigeria.
Int J Tuberc Lung Dis. 2020;24:981-982.
PubMed

VAN DER WALT M, Keddy KH
How COVID-19 can instruct TB research: ensuring the safety of researchers exposed to infectious disease.
Int J Tuberc Lung Dis. 2020;24:978-980.
PubMed

WILSON FA, Miller TL, Stimpson JP
COVID-19 and TB control in immigrant communities.
Int J Tuberc Lung Dis. 2020;24:975-977.
PubMed

ECHEVERRIA G, Espinoza W, de Waard JH
How TB and COVID-19 compare: an opportunity to integrate both control programmes.
Int J Tuberc Lung Dis. 2020;24:971-974.
PubMed

MULDER C, Nkiligi E, Kondo Z, Scholten JN, et al
What to look for when using SUBsET for subnational TB incidence estimates.
Int J Tuberc Lung Dis. 2020;24:983-984.
PubMed

WANG J, Garcia-Basteiro AL
Should vitamin D supplementation be used concomitantly with LTBI treatment?
Int J Tuberc Lung Dis. 2020;24:875-876.
PubMed

August 2020

CHIANG CY
Green Light Committee and WHO recommendations.
Int J Tuberc Lung Dis. 2020;24:873-874.
PubMed

June 2020

HARRIES AD
In Response to Reinout van Crevel et al.
Int J Tuberc Lung Dis. 2020;24:634.
PubMed

May 2020

FURIN J
Can Green Light Committees help "end TB"?
Int J Tuberc Lung Dis. 2020;24:540.
PubMed

April 2020

BASHAM CA, Romanowski K, Johnston JC
Cardiovascular disease: the forgotten cousin of post-TB health?
Int J Tuberc Lung Dis. 2020;24:466-467.
PubMed

Thank you for your interest in scientific medicine.

AMEDEO Tuberculosis is free of charge.